

# 1 Global projections of potential lives saved from COVID-19 through 2 universal mask use

3 IHME COVID-19 Forecasting Team

## 4 Abstract

5 *Background:* Social distancing mandates have been effective at reducing the health impacts of COVID-  
6 19. The ensuing economic downturns and unemployment increases have led many nations to  
7 progressively relax mandates. As COVID-19 transmission and deaths rise in many low and middle-income  
8 countries (LMICs), with continuing widespread transmission elsewhere, policymakers are searching for  
9 options to reduce COVID-19 mortality without re-imposing strict social distancing mandates.

10 *Methods:* Using a Bayesian meta-regression of 40 studies measuring the impact of mask use on  
11 respiratory viral infections, we estimated the reduction in transmission associated with the use of cloth  
12 or paper masks used in a general population setting. We used data from daily surveys conducted by  
13 Facebook, YouGov, and Premise, on the proportion of people reporting always wearing a mask outside  
14 their home for nearly all countries. We predicted deaths and infections until January 1<sup>st</sup> 2021 under a  
15 reference and universal mask use scenario using a deterministic transmission dynamics model with  
16 categories for susceptible, exposed, infected and recovered (SEIR). In the reference scenario, we assume  
17 continued easing of mandates but with action to re-impose mandates for a period of six weeks, at a  
18 level of eight daily deaths per million population. The universal mask scenario assumed scaling up of  
19 mask use to 95% over a one-week period.

20 *Findings:* Use of simple masks can reduce transmission of COVID-19 by 40% (95% uncertainty interval  
21 [UI] 20% – 54%). Universal mask use would lead to a reduction of 815,600 deaths (95% UI 430,600 to  
22 1,491,000 deaths) between August 26<sup>th</sup> 2020 and January 1<sup>st</sup> 2021, the difference between the  
23 predicted 3.00 million deaths (95% UI 2.20 to 4.52 million) in the reference and 2.18 million deaths (95%

24 UI 1.71 to 3.14 million) in the universal mask scenario over this time period. Mask use was estimated at  
25 59.0% of people globally on August 18<sup>th</sup>, ranging from 41.9% in North Africa and the Middle East to  
26 79.2% in Latin America and the Caribbean. The effect of universal mask use is greatest in countries such  
27 as India (158,832 fewer deaths in universal mask scenario, 95% UI 75,152 to 282,838 deaths), the United  
28 States of America (93,495 fewer deaths; 95% UI 59,329 to 150,967 deaths), and Russia (68,531 fewer  
29 deaths; 95% UI 34,249 to 145,960 deaths).

30 *Interpretation:* The rising toll of the COVID-19 pandemic can be substantially reduced by the universal  
31 adoption of masks. This low-cost policy, whether customary or mandated, has enormous health benefits  
32 and likely large economic benefits as well, by delaying the need for re-imposition of social distancing  
33 mandates.

34

## 35 Research in context

### 36 **Evidence before this study**

37 One meta-analysis of 21 studies reported a pooled reduction in the risk of respiratory virus infection of  
38 47% (95% CI 36-79%) from a subset of eight studies reporting on mask use in non-health workers but it  
39 did not distinguish type of mask. Another meta-analysis reported on 26 studies of mask use in health  
40 workers and three studies in non-healthcare settings, reported a pooled effect of a 66% (55-74%)  
41 reduction in infections and a reduction by 44% (21-60%) in the three non-healthcare setting studies.  
42 Several survey series regularly measure self-reported mask use but results from these different sources  
43 have not previously been pooled to derive daily estimates of mask use over the course of the epidemic.  
44 Global models of the impact of scaled up mask use have to our knowledge not been published.

### 45 **Added value of this study**

46 We combined the studies on mask use identified in the two meta-analyses and added one further study.  
47 In a Bayesian meta-regression approach, we derived the effect of simple cloth or paper masks used  
48 outside of a healthcare setting. In the meta-regression we make use of all the information provided by  
49 all of these studies, rather than subsetting to just those studies that provided the direct comparison of  
50 interest. Pooling estimates on the prevalence of self-reported mask use from three survey series  
51 provides up-to-date information on trends in mask use in almost all countries. We use extensive survey  
52 data covering nearly every country in the world to assess recent trends and current mask use. We then  
53 use an SEIR transmission dynamics model with good predictive validity to assess the potential of scaled  
54 up mask use to reduce global mortality from COVID-19.

### 55 **Implications of all the available evidence**

56 Universal mask use can save many lives and avoid or, at least, delay the need for re-imposition of social  
57 mandates (such as stay-at-home orders, curfews, *etc.*), which would also contribute to ameliorating the  
58 negative effects of COVID-19 on the economy and unemployment. Until an affordable vaccine becomes  
59 universally available, mandating mask use is the most attractive policy option available to all countries,

60 particularly if an expected increased transmission risk occurs in the Northern hemisphere's fall and  
61 winter. Simple face coverings are cheap and effective; one of the few available interventions that is  
62 widely available to everyone. Countries with currently low mask use will need to determine the optimal  
63 balance between encouraging the use of masks through advocacy and information about their benefits,  
64 and governance of a compulsory use associated with penalties for non-compliance.

65

## 66 Introduction

67 COVID-19 has spread to all regions of the world and as of August 30<sup>th</sup> 2020, with over 25 million cases  
68 and 845,414 deaths have been reported globally<sup>1</sup>. This is undoubtedly an underestimate and only one  
69 direct measure, among many, that may be used to refer to the impact of the pandemic on health and  
70 health systems around the world. In March 2020, nearly all nations put in place a set of social distancing  
71 mandates that have contributed to blunting the effects of COVID-19. Economic downturns and the  
72 associated mass unemployment caused by these measures has led most nations to progressively relax  
73 social distancing mandates. As COVID-19 transmission and deaths rise in many low and middle-income  
74 countries (LMICs) and some high-income countries, policymakers are keen to identify policy options to  
75 reduce COVID-19 mortality without re-imposing strict social distancing mandates.

76 One attractive strategy is the imposition of mandates requiring the wearing of masks in public spaces  
77 when physical distancing is not feasible. Initially, the World Health Organization (WHO) discouraged  
78 mask use by public questioning of the evidence supporting general use and arguing it might lead to mask  
79 shortages for healthcare providers<sup>2,3</sup>. Several systematic reviews, however, have suggested that cloth  
80 and other non-medical masks worn by the general public can markedly reduce transmission.<sup>4,5</sup> A  
81 growing number of national and local governments have recently adopted mask use mandates, with  
82 now over 150 countries mandating mask use either nationally, or in specific transmission hotspots,  
83 focused in enforcing their use within on public transit or indoor public spaces.<sup>6</sup> In nations such as the  
84 United States (US) and Brazil, mask use has become a political issue, with widely varying viewpoints on  
85 the ethics, legality and enforcement of mask use mandates.<sup>7,8</sup> Evidence of the individual benefits,  
86 population health impacts, and the potential economic benefits of increased mask use may be a useful  
87 input in these national debates.

88 Masks can affect the transmission of respiratory pathogens in a number of ways, thereby providing a  
89 complement to stringent social distancing mandates without the associated severe economic impacts,

90 and in settings such as indoor public spaces where distancing may not be possible. Simple cloth masks  
91 are also affordable and equitably accessible. At the individual level masks reduce transmission *via* a  
92 physical barrier whereby the force of exhalation, coughing, or sneezing leads to impaction and  
93 interception of viral droplets ( $> 5\mu\text{m}$  in diameter) and aerosol ( $\leq 5\mu\text{m}$  in diameter, resulting from  
94 evaporation of expired droplets, also described as droplet nuclei) onto the fibers of the mask.<sup>9-11</sup> Given  
95 greater impaction efficiency for droplets, masks are most effective in blocking outward exhalation<sup>12</sup>,  
96 although evidence from studies of air pollution aerosol indicates some protection of non-medical masks  
97 in blocking a small fraction of aerosol inhalation.<sup>13</sup> Thus mask wearing is effective both for the infected  
98 and the uninfected<sup>14</sup> and is also relevant to the recent discussions regarding airborne transmission of  
99 SARS-CoV-2.<sup>15</sup> Airborne transmission is, by definition, caused by droplet nuclei (*i.e.* evaporated droplets)  
100 that may remain infectious when suspended in the air over extended distances or time periods.<sup>11</sup> As  
101 masks can effectively block exhalation of droplets, they also reduce production of droplet nuclei by  
102 evaporation, and therefore offer a practical intervention against airborne transmission to complement  
103 ventilation and less widely accessible interventions such as air filtration and UV disinfection.

104 In this paper, we provide a meta-regression of the reduction in transmission associated with mask use,  
105 use survey data to assess current levels and trends in use of masks globally, and quantify the benefits of  
106 universal mask use (here defined as 95% of individuals always wearing a mask when outside their home)  
107 on COVID-19 mortality using a COVID-19 transmission dynamics model. We provide estimates of lives  
108 saved through universal mask use globally and at the national level between July 26<sup>th</sup> 2020 and January  
109 1<sup>st</sup> 2021.

110

## 111 Methods

112 Our analysis is comprised of three main components: a literature scoping analysis and meta-regression  
113 of the benefits of mask use with an emphasis on non-medical mask use amongst the general (non-  
114 healthcare) population; an analysis of survey data on the levels and trends in mask use; and modeling  
115 two scenarios (reference and universal mask use) of COVID-19 incidence and death using a deterministic  
116 transmission dynamics model with categories for susceptible, exposed, infected and recovered (SEIR).  
117 Each component is discussed in more detail below.

### 118 Estimating the effectiveness of masks in preventing transmission

119 We performed a meta-regression of 63 observations from 40 studies of the effectiveness of masks in  
120 preventing the transmission of respiratory virus infections. These studies were included in two published  
121 meta-analyses<sup>4,5</sup> with one further study of mask use for COVID-19 in the general population added.<sup>16</sup>  
122 The studies varied in setting (general population versus healthcare), type of mask (which we  
123 dichotomized into medical-grade masks, including surgical and N95 masks, and non-medical masks,  
124 including cloth masks), comparator group (no mask use or “occasional” mask use), type of diagnosis  
125 (clinical or laboratory), country of study (dichotomized into Asian and non-Asian countries) and type of  
126 respiratory virus (SARS-CoV-1 or 2 versus H<sub>1</sub>N<sub>1</sub>, influenza, or other respiratory viruses); details on the  
127 details of all included studies<sup>16–55</sup> can be found in SI Table 2 in the Appendix. From the identified papers,  
128 we extracted all relevant observations that assessed mask effectiveness, allowing for multiple  
129 observations per study based on variations in mask type, virus studied, or comparison group. From the  
130 two meta-analyses, four identified studies were excluded where a relative risk was not available<sup>56,57</sup>, we  
131 were unable to extract mask use from general PPE use<sup>58</sup>, or because the comparison group was of less  
132 protective masks rather than no or infrequent mask use<sup>59</sup>. In order to derive the most relevant pooled  
133 estimate for the effect of mask use on preventing the spread of COVID-19 in populations, we performed  
134 a meta-regression of all 63 observations and their characteristics to predict the effect of non-medical

135 mask use in a community setting to prevent laboratory-confirmed SARS-CoV-2 compared to no use of  
136 masks. For studies with zero counts in the numerator, we used a continuity correction of 0.001 to  
137 estimate the RR in order to ensure inclusion in our analyses; sensitivity analyses considering other  
138 continuity corrections produced highly consistent results (see Appendix). To generate summary  
139 estimates we used a custom Bayesian mixed-effects meta-regression tool (MR-BRT – “meta-regression –  
140 Bayesian, regularized, trimmed”)<sup>60</sup> which accounted for between-study heterogeneity in the width of  
141 the uncertainty interval (see Appendix for more details).

#### 142 [Past, current and future prevalence of mask use](#)

143 We used three main sources of data on self-reported use of masks: the Facebook Global Symptom  
144 Survey<sup>61</sup>, the PREMISE surveys<sup>62</sup>, and the YouGov COVID-19 Behaviour Tracker surveys.<sup>63</sup> Between April  
145 23<sup>rd</sup> and August 18<sup>th</sup>, Facebook has surveyed 23.3 million Facebook users from 102 countries using an  
146 instrument with multiple items on behaviours related to COVID-19, including mask use. For the US, we  
147 used data collected through PREMISE. There were 190,216 total PREMISE responses representing all 50  
148 states and the District of Columbia with responses collected between April 21<sup>st</sup> and August 21<sup>st</sup>. The  
149 YouGov surveys cover 29 countries and have interviewed around 493,400 individuals since March 1<sup>st</sup> and  
150 up until August 8<sup>th</sup> 2020. From the Facebook surveys, we used the item: “In the last 7 days, how often  
151 did you wear a mask when in public?” to which there are the following responses “All of the time; Most  
152 of the time; About half of the time; Sometimes; Never; I have not been in public during the last 7 days”.  
153 Respondents for “All of the time” were the numerator in our proportion. From the PREMISE surveys, we  
154 use the following question: “When you leave your home do you typically wear a face mask  
155 (SELECT\_ONE)” with responses “Yes, always; Yes, sometimes; No never”. Respondents for “Yes, always”  
156 were the numerator in our proportion. From YouGov, we use the following question: “Thinking about  
157 the last 7 days, have you worn a face mask outside your home (e.g. when on public transport, going to a



158 supermarket, going to a main road)” with responses “Always”, “Frequently”, “Sometimes”, “Rarely”, and  
159 “Not at all”. Respondents for “Always” were the numerator in our proportion.

160 Mask use for each location was estimated using a spline-based smoothing process. This smoothing  
161 process averages each data point with five neighboring data points. To arrive at smooth, flat values at  
162 the ends of the observed data, we computed the average of the change in mask use over the three  
163 following days (left tail) and three preceding days (right tail). For locations without data on mask use, we  
164 used, in order of preference, national level estimates (for subnational locations), regional estimates, and  
165 super-regional estimates based on the regional groupings used by the Global Burden of Disease Study  
166 (GBD). The only exception was for countries in Oceania, a region where no data are available through  
167 any of the three survey platforms. In the GBD hierarchy, these countries are part of the East Asia and  
168 Southeast Asia super-region; however, mask use in Oceania is likely to be more similar to mask use in  
169 Australia and New Zealand and so the mask use from that region was used for countries in Oceania.

170 To construct our scenario of universal mask use, we assume that current mask use in all locations would  
171 increase to 95% over the course of 7 days. We use 95% as that is the highest level of mask use reported  
172 at the national level to date during the COVID-19 pandemic; this level was reported in Singapore. Our  
173 “universal mask use” scenario assumes that this level of mask use can be achieved through the adoption  
174 and enforcement of mask use mandates around the world.

#### 175 [COVID-19 SEIR model construction for each location](#)

176 The IHME COVID-19 prediction model has been described in detail elsewhere.<sup>64</sup> For the results  
177 presented in this analysis, the SEIR part of the model are most relevant. We construct an SEIR model for  
178 each location we model; the Appendix shows the basic states included in the model and the transition  
179 parameters. The critical driver of the epidemic is the rate at which susceptible individuals become  
180 infected in each location which is assumed to be represented as:

190 
$$\frac{dS}{dt} = -\beta(t) \frac{S(I_1 + I_2)^\alpha}{N}$$

181 Where  $\beta_t$  is the transmission parameter for time period  $t$ ,  $\alpha$  represents a mixing coefficient to account  
182 for imperfect mixing within each location,  $S$  is the fraction of each location's population that is  
183 susceptible, and  $I_1$  and  $I_2$  is the fraction that are infectious. Effective  $R_t$ , the number of new infections  
184 caused by each case is a simple monotonic transformation of  $\beta_t$  and the fraction of the population that is  
185 susceptible. We use an efficient algorithm to directly estimate  $\beta_t$  in the past – see appendix for details.  
186 To determine the strength of the relationship between  $\beta_t$  and various covariates, we perform a log-  
187 linear regression using the open source mixed effects solver SLIME<sup>5</sup>. All covariates are assumed to have  
188 fixed effects while the intercept is allowed to vary by location. For location  $l$ , the regression is calculated  
189 as:

191 
$$\ln(\beta_{p,l}) = \alpha_{0,l} + \mathbf{X}_l \boldsymbol{\alpha}$$

192 where  $\alpha_{0,l}$  is the random intercept for location  $l$ ,  $\mathbf{X}_l$  is a matrix with a column for each covariate in the  
193 regression and a row for each day, and  $\boldsymbol{\alpha}$  is the coefficient indicating the strength of the relationship  
194 between  $\log \beta$  and each of the covariates. We tested many covariates and included the following in the  
195 model: population density measured as the share of the population living in areas with more than 2,500  
196 individuals per square kilometer, the fraction of the population living below 100 meters above sea level,  
197 smoking prevalence, particulate matter air pollution (PM2.5 population-weighted annual average  
198 concentration), mobility measured using cell phone apps, mask use, COVID-19 testing *per capita*, and  
199 pneumonia seasonality. Pneumonia seasonality was constructed as an index using medical certification  
200 of cause of death data on pneumonia deaths by week and normalized annually. In locations without 4-  
201 or 5-star quality cause of death data<sup>65</sup>, we used latitude as a predictor of the pattern of pneumonia  
202 seasonality. To avoid over-estimating the effects of pneumonia seasonality and mask use we used  
203 constraints on each in the regression – see Appendix for details. Specifically, for mask use, we did not let

204 the regression estimate an effect size larger than what was consistent with the mask use meta-analysis  
205 of the individual level effect. To capture uncertainty in the input data, model parameters and regression  
206 coefficients linking  $\beta_{jt}$  to covariates, we generated 1,000 models for each location – see Appendix for  
207 details.

208 We evaluated out of sample predictive validity for this modeling approach by holding out the last five  
209 weeks of data and compared predictions from the held-out data to what occurred; median absolute  
210 percent error for cumulative deaths at five weeks was 7%.<sup>66</sup> We also compared this model to other  
211 COVID-19 prediction models that make their estimates publicly available; overall, we find that our model  
212 has the best performance at 5- and 6-weeks out-of-sample.<sup>66</sup>

213 We used the set of 1,000 SEIR models for each location to generate two types of scenarios: a reference  
214 scenario and a universal mask use scenario. In the reference scenario, or what we think is most likely to  
215 occur, key drivers such as mobility and testing *per capita* evolve according to past trends – see Appendix  
216 for details. In the universal mask use scenario, we assume that mask mandates and other campaigns  
217 lead to scale-up of mask use to 95% within seven days of enactment. We also assume both in the  
218 reference and in the universal mask use scenario that social distancing mandates would be re-imposed  
219 when the daily death rate reaches eight per million people per day. This daily death rate represents the  
220 90<sup>th</sup> percentile across countries of the observed daily death rate in the past few months before each  
221 country imposed the maximum number of social distancing mandates. This daily death rate also  
222 represents the observed average daily death rate to date among the small number of locations that are  
223 experiencing a resurgence and are re-imposing social distancing mandates.

## 224 Results

225 Figure 1 shows the relative risk of viral respiratory infection among users of different types of  
226 facemasks. Studies of general population use (13 observations of 63 total) included cluster randomized  
227 trials of household member mask use living with an infected individual, cohort analyses of close contacts  
228 of infected individuals, and case control analyses of mask use prior to infection amongst the general  
229 population or of secondary infections amongst household members of an infected individual. A total of  
230 19 observations were of non-medical masks, with eight of these focused on use by the general public.  
231 The meta-regression suggested the benefits of non-medical masks in the general population to be a 40%  
232 (UI 20% – 54%) reduction in transmission. The benefits of wearing surgical or medical masks in the  
233 general population were slightly larger, a 43% reduction (23% - 59%) in transmission. Even larger  
234 reductions in transmission were estimated for non-medical (54% [40%-64%] and medical (56% [48%-  
235 64%]) mask use amongst healthcare worker populations. More details are provided in the Appendix.

236 Based on survey data collected through smartphone hosted questionnaires, Figure 2 shows a map of  
237 mask use by location as of August 18<sup>th</sup>, the last date of fully observed data in the model. Mask use is  
238 high in most parts of Latin America and South-East and East Asia. The highest mask use on August 18<sup>th</sup>  
239 was in Chile (93.6%), followed by Puerto Rico (93.5%), and Guatemala (92.2%). The lowest rates are seen  
240 in Northern Europe (Sweden, Norway, and Denmark < 1%) and North Africa (Tunisia 6.5%). Lower rates  
241 are seen in some parts of sub-Saharan Africa, Northern Europe, and states and provinces in the United  
242 States, Canada, and Australia. Mask use is highest among people who live in cities and lowest in people  
243 who live in rural communities (see Appendix).

244 Figure 3 shows the global and super-region trends in mask use since the beginning of the epidemic.  
245 Mask use data start only in the beginning of April so the rapid expansion from likely a very low baseline  
246 pre-COVID-19 outside of East Asia most probably occurred in March. Mask use was estimated at 59.0%  
247 of people globally on August 18<sup>th</sup>, ranging from 41.9% in North Africa and the Middle East to 79.2% in

248 Latin America and the Caribbean (Figure 3). Mask use has increased in some locations where mandates  
249 have been put into place such as Australia, Belgium, and the United Kingdom (SI Figure 7). Mask use has  
250 declined in some settings where death rates are declining such as Poland, Czechia, and Italy (SI Figure 7).  
251 Mask use varied by gender in some regions, with higher use by females in all regions except for South  
252 Asia, (globally 54.2% in females vs to 52.3% in males) and by age with generally lower use amongst 18-  
253 24 year olds (50.0%) and those over 65 years (46.4%) compared to 55-54 year old adults (56.5%) who  
254 were the most likely to wear masks (percentages on July 21, see Appendix).

255 Global projections of COVID-19 deaths with and without a universal mask use mandate are shown in  
256 Figure 4. In our reference scenario, we expect daily COVID-19 deaths to increase in October through  
257 December leading to 3.00 million deaths (95% UI 2.20 to 4.52 million) by January 1<sup>st</sup> 2021. Uncertainty in  
258 daily deaths and cumulative deaths widens steadily over time such that there is considerable  
259 uncertainty in global deaths by January 1<sup>st</sup>. In contrast, the universal mask use scenario leads to a mean  
260 estimate of 2.18 million deaths (95% UI 1.71 to 3.14 million) by January 1<sup>st</sup>. The difference in mortality  
261 between the reference and universal mask use scenario suggests that 0.82 million lives (95% UI 0.43 to  
262 1.49 million) could be saved over this time period if 95% of people were to always wear masks when  
263 outside their home. Table 1 provides estimates by location of the expected deaths in the reference and  
264 universal mask use scenario along with the number of deaths saved through the mask use mandate. The  
265 countries where mask mandates would have the largest effect are populous countries such as India  
266 (158,832 fewer deaths in universal mask scenario, 95% UI 75,152 to 282,838 deaths), the United States  
267 of America (93,495 fewer deaths; 95% UI 59,329 to 150,967 deaths), and Russia (68,531 fewer deaths;  
268 95% UI 34,249 to 145,960 deaths). The greatest magnitude difference in mortality rate occurred in the  
269 Netherlands (23,282 fewer deaths, 136 deaths per 100,000), Switzerland (6,062 fewer deaths, 86 deaths  
270 per 100,000).

271 Figure 5 shows a map of the percent reduction in expected deaths from the reference scenario  
272 compared to the mask use scenario in the deaths from August 28<sup>th</sup> to January 1<sup>st</sup>. The largest percent  
273 reduction in expected deaths occurred in Tanzania (80.4% difference, 95% UI 63.4 to 94.4%), Poland  
274 (78.8% difference, 95% UI 60.4 to 93.5%), and Algeria (78.4% difference, 95% UI 61.9 to 92.2%).  
275 Expected deaths were greater in the universal mask use scenario than in the reference scenario in some  
276 locations due to the delay in re-imposition of mandates such as in Kazakhstan (more deaths in mask use  
277 scenario, 95% UI 7.2 to 45.3% increase). There are large variations in the number of lives saved globally,  
278 regionally, nationally, and subnationally and these are detailed in full in Table 1.

279

## 280 Discussion

281 Wearing a mask reduces the risk of contracting COVID-19 for individuals by 40% (20%-54%). Given global  
282 mask use is currently at 59.0%, increasing mask use to 95% through mandates could decrease  
283 cumulative COVID-19 deaths by January 1<sup>st</sup> 2021 by 0.82 million deaths (95% UI 0.43 to 1.49 million).  
284 This represents a 26.5% reduction in the number of deaths expected from August 28<sup>th</sup> to January 1<sup>st</sup>  
285 2021. The benefits of increased mask use are greatest in settings with ongoing substantial transmission  
286 and low current levels of mask use regardless of sociodemographic status. Our models also show that in  
287 many settings, increased mask use will delay the need re-imposition of social distancing mandates by  
288 many weeks or even months; in addition to the lives saved, a delay in re-imposition of social mandates  
289 might also be accompanied by substantial economic benefits.

290 The estimate of 40% effectiveness of non-medical mask use by the general public is based on 13  
291 observations (from 9 studies) specific to the general population, from a total of 63 observations from 40  
292 separate studies included in the meta-regression. The uncertainty interval is wide, from 20% to 54%  
293 reduction in transmission. Even with this uncertainty interval, there was absolutely no indication of any

294 harmful impacts of mask use, such as tendencies for engaging in riskier behaviour or self-contamination  
295 *via* more frequent face touching, as has been suggested.<sup>67,68</sup> Further, the published studies of SARS-CoV-  
296 2 included in our analysis of mask effectiveness demonstrated reductions in relative risk of 30% - 100%,  
297 with the one study of non-medical mask use amongst the general population, indicating a reduction of  
298 42% for any mask use and 70% for consistent mask use.<sup>69</sup> Mask effectiveness is also supported by  
299 additional evidence from laboratory studies that report on the efficacy of masks in reducing exhalation  
300 of both aerosols and droplets by those infected with SARS CoV-2.<sup>70</sup> Further, a recent case series  
301 reported no secondary infections among 139 individuals exposed to two symptomatic hair stylists with  
302 confirmed COVID-19 while both the stylists and their clients wore masks.<sup>71</sup> In addition, a study of Swiss  
303 soldiers indicated that physical distancing and use of medical masks led to no COVID-19 symptoms  
304 despite the presence of virus-specific antibodies<sup>72</sup>, while a study of healthcare workers indicated that  
305 universal use of medical masks was associated with lower rate of SARS-CoV-2 positive tests<sup>73</sup>. Based on  
306 all types of available evidence, it seems critical to encourage mask use throughout the world as the  
307 benefits can be substantial with low to zero contraindications. Guidance for specific materials, handling  
308 of face coverings and other considerations is rapidly evolving as additional evidence emerges<sup>74</sup>.

309 At the population level, the regression analysis of the determinants of the transmission parameter  
310 suggests a much larger effect of mask use than the one seen in the published studies. To avoid the risk  
311 of over-stating the benefits of mask use in this analysis, however, we have constrained the regression to  
312 yield results that are consistent with the range of the effect sizes found in the individual level studies. In  
313 other words, the benefits of a universal mask use mandate could be substantially larger and what we  
314 report here can be seen as a conservative estimate of the impact of mask use on lives saved.

315 Given that the cost of masks is very low, mask mandates and/or the promotion of mask use seems  
316 prudent, as the risk of adopting these policies is minimal and the potential benefits very large. In  
317 recognition of this, over the last few months we have seen the number of countries and territories with

318 mask mandates in place increase substantially. Nevertheless, there remains reluctance to adopt mask  
319 use and to impose mask mandates. In some settings, the current epidemiological context means that  
320 mask wearing is not viewed as a necessary part of control, such as in Norway where the Norwegian  
321 Institute of Public Health determined that, given their current low prevalence, “200,000 people would  
322 need to wear facemasks to prevent one new infection per week.”<sup>75</sup> In other settings however, despite  
323 increasing cases, public sentiment towards mask wearing hinders universal utilization. Past messages  
324 from some governments have not encouraged mask use and may have actually discouraged mask use.<sup>76–</sup>  
325 <sup>78</sup> Early on, WHO stated “*the wide use of masks by healthy people in the community setting is not*  
326 *supported by current evidence and carries uncertainties and critical risks*”<sup>2</sup> and only changed their official  
327 position on June 5<sup>th</sup> to encourage mask use.<sup>79</sup> This reluctance to embrace mask use given no real risks of  
328 use and considerable potential health and economic benefits is hard to understand and justify. For those  
329 decision-makers who are concerned with the economic effects of social distancing mandates, mask use  
330 mandates provide a low-cost strategy to reduce the risk of a further round of social distancing mandates  
331 and the associated unemployment and economic downturn.

332 While the effective R, the number of new infections created by a single infection under the auspices of  
333 control, can potentially be reduced by one-third through universal mask use compared to no mask use,  
334 mandates alone will likely be insufficient to control the epidemic in many locations. Even with universal  
335 mask use, we expect the death toll due to COVID-19 to reach 2.18 million deaths by the end of the year,  
336 and many more in 2021, assuming an efficacious vaccine is not discovered, licensed and widely deployed  
337 in the interim. Countries will have to consider other policy strategies to reduce transmission, including  
338 increasing testing, contact tracing, and isolation, along with “smart mandates”, which refers to targeting  
339 mandates or restrictions to particular subgroups of the population, such as specific age-groups or local  
340 communities for short periods of time. A central policy challenge for many countries is understanding



341 which of these mandates targeting strategies makes the most sense in a given context and at what level  
342 of COVID-19 transmission. This is the focus of our ongoing work.

343 The findings of this study should be interpreted while taking into account its limitations. First, there is a  
344 set of limitations related to the meta-regression, including the following. The number of published  
345 studies on the protection provided by cloth masks worn by the general public is limited. With rapid  
346 development of the COVID-19 literature, new data on the effectiveness of masks can quickly be  
347 incorporated into our meta-regression model. Future studies could change our pooled estimate of the  
348 effect size and/or the large uncertainty interval around it in the meta-regression. As we looked at  
349 multiple observations per study, it was not really feasible to account for all possible clustering. We  
350 performed sensitivity analyses (shown in the Appendix) and found minimal differences in investigating  
351 the role of clustering in our results. Studies had different endpoints and while we controlled for that in  
352 our meta-regression, it would be ideal to have more studies that focus on COVID-19 as an endpoint.

353 Second, related to the modeling framework, we use an SEIR model to predict the course of the epidemic  
354 with and without universal mask use. In general, SEIR models have tended to overestimate the  
355 infections and deaths associated with COVID-19. Over-estimation is likely due to the fact that individuals  
356 change their behaviours as the epidemic gets worse around them and governments tend to react when  
357 hospital systems are nearing capacity. We have built the government response into our reference  
358 scenario and have tried to use empirically observed data on mobility and current mask use to reflect the  
359 individual behavioural response. Further, our model makes a number of simplifying assumptions  
360 associated with mixing and transmission heterogeneity and as such, our conclusions must be considered  
361 with these assumptions in mind. Also, we use a log-linear mixed regression which does not take into  
362 account the potential for non-linear relationships. We acknowledge that there are likely non-linear  
363 relationships between some of the drivers of transmission and transmission intensity. Moreover, we  
364 expect there to also be complex lagged relationships between covariates and transmission (e.g., fatigue

365 related to duration of mandate altering its impact on transmission). Improving how our model uses  
366 covariates to capture temporal variation in new infections is an open avenue of research.

367 Third, our out-of-sample predictive validity testing has shown that errors tend to progressively get larger  
368 the longer the forecast, but has also shown that errors are much larger in settings where there are  
369 fewer than 50 total deaths to date. For example, predictions from publicly available models for sub-  
370 Saharan Africa have been particularly bad.<sup>66</sup>

371 Fourth, we assume cases and deaths are accurately reported by JHU except in Ecuador, Kazakhstan and  
372 where excess mortality analyses have indicated substantial underreporting of COVID-19 deaths. Other  
373 countries may not be detecting or reporting deaths and cases due to lack of testing or other  
374 considerations. Overall, though, we believe that our prediction model performs well and where antibody  
375 tests have been conducted at the population level, we have found our model based on deaths has  
376 matched these results.<sup>64</sup>

377 Fifth, our models are sensitive to the trends in the last 7-14 days in deaths and somewhat sensitive to  
378 the trend in cases. In settings where deaths and cases are steadily rising, the model will tend to have  
379 large estimates of  $\beta_t$ . If the rise in transmission is not captured by trends in mobility or other covariates,  
380 the unexplained residual in the model increases and this is then reflected in the forecasts by day  
381 through to January 1<sup>st</sup>. The reverse relationship also holds true for when there is a consistent downward  
382 trend. The sensitivity of our model to data trends is a strength in that it makes our models reflect the  
383 on-the-ground realities; it is also a challenge in the sense that our model results will change when there  
384 are changes in recent transmission that are not captured by the covariates.

385 Sixth, we rely on self-reported data which is collected via mobile phone app-based surveys on use of  
386 masks. In addition to the usual biases that accompany self-reported data, in this case we do not know  
387 whether in settings with mask mandates in place, respondents may be reporting their behavior

388 differently compared to settings without mask mandates. The respondents to app-based surveys are  
389 also likely to not be a truly representative sample of the populations in each location. The degree to  
390 which the respondents represent the general population varies across locations, and depends on the  
391 prevalence of Facebook and other app use in each country. While this is a limitation of the data that are  
392 currently available, we believe that given the samples tend to be biased towards more educated, urban,  
393 and younger populations, the reported mask use is likely to be an over-estimate in these locations. If  
394 this is true, then the estimates of the impact of expanding mask use to reach 95% coverage in these  
395 populations would be an underestimate of the true effect of the intervention.

396 These limitations highlight important areas for improvement across the entire spectrum of research  
397 related to COVID-19. There is a critical need for more and higher quality data across the spectrum of  
398 information required to understand the trajectory of this pandemic, starting with better and higher-  
399 quality information on the numbers of cases and deaths, to improved and more representative data on  
400 use of masks among populations across the world, to additional studies that quantify the effect of face  
401 coverings on transmission probability of SARS-COV2 among the general population, to better data on  
402 social distancing mandates implemented in each location and the extent to which they are enforced. On  
403 the modeling side, continued work on making modeling frameworks more flexible and including  
404 alternative model specifications, as well as improving on how covariates are used to capture temporal  
405 variation in new infections might lead to improvements in the performance of long-range forecasts. A  
406 greater understanding of how the drivers of this pandemic interact with each other and affect  
407 transmission probabilities is critical for influencing its trajectory over the next few months.

## 408 Conclusion


409 The COVID-19 epidemic is far from over. While a selection of therapeutics is showing promise, a vaccine  
410 that can be deployed at global scale does not exist and is unlikely to be widely available in the near

411 future. We expect more deaths in the second half of 2020 than were seen in the first six months. Not  
412 only are there large epidemics unfolding in Latin America, the Middle-East and South Asia, but  
413 seasonality suggests a second wave can be anticipated in the Northern Hemisphere. The rising toll of the  
414 COVID-19 pandemic can be reduced by 0.82 million deaths in the next few months by the adoption of  
415 universal mask mandates. This low-cost intervention that is available and accessible to all populations,  
416 regardless of socio-economic status or other dimensions of inequity, has enormous health benefits and  
417 might also lead to large economic benefits by delaying the need for re-imposition of social distancing  
418 mandates. In global health we rarely encounter effective, low-cost, and universally available  
419 interventions that can save lives: immediately, equitably and safely. Ensuring that individuals, as well as,  
420 local, national and global decision makers are all doing everything in their power to achieve the highest  
421 rates of mask use in all exposed populations is one of the best strategies available to us to mitigate the  
422 toll of the pandemic in the months to come.

423

424 **Figures**

425 **Figure 1. Relative risk of viral respiratory infection among users of different types of facemasks.**



426

427 This analysis includes only variables addressing facemask type (non-medical versus medical) and population type of

428 mask user (general population versus healthcare setting). The size of the box is proportional to the precision of the


429 estimate, based on number of observations, with more precise studies having larger boxes.

430

431

432

433 **Figure 2. Proportion of the population that self-report always wearing a facemask when outside the**  
434 **home on July 21, 2020.**



435

436

437


438

439

440

441

442 **Figure 3. Proportion of the population that self-report always wearing a facemask when outside the**  
443 **home by Global Burden of Disease study super-region between March 1, 2020 and September 30,**  
444 **2020. Values after the last date of observed survey data are dashed lines and horizontal projections**  
445 **from the last observed values.**




446

447

448

449

450 **Figure 4. Projected global deaths due to COVID-19 up to January 1, 2021 in the scenario for current**  
451 **projections of mask use and the scenario with 95% coverage of mask use. Projections are shown for**  
452 **the world and for the seven super-regions as defined in the Global Burden of Disease Study.**




453

454



455 **Figure 5. Percent reduction in cumulative deaths on January 1, 2021 in the universal mask use**  
456 **scenario and the reference scenario.**



457  
458  
459 Areas have “no estimates” either because of no available data or because the population size, cases or deaths are  
460 so small that the SEIR models do not run.  
461

**Table 1. The difference in cumulative deaths between the universal mask use scenario and the reference (current mask use) scenario globally and for each GBD super-region, region, country, and first administrative subnational on January 1, 2021.**

Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
<b>Global</b>	815564 (430556 to 1490969)	-26.5% (-37.1 to -19.1%)	2996714 (2198771 to 4516689)
<b>Central Europe, Eastern Europe, and Central Asia</b>	134421 (64565 to 280696)	-57.7% (-75 to -43.4%)	224915 (143896 to 388691)
<b>Central Asia</b>	2408 (-2708 to 12197)	-6.8% (-29.1 to 10.3%)	30369 (16348 to 53472)
Armenia	1010 (427 to 2641)	-39.3% (-57.9 to -25.7%)	2441 (1601 to 4671)
Azerbaijan	54 (6 to 243)	-7.8% (-29.2 to -1.1%)	620 (557 to 826)
Georgia	0 (0 to 0)	0% (-0.1 to 0%)	17 (17 to 18)
Kazakhstan	-3413 (-7647 to -923)	20% (7.2 to 45.3%)	17510 (7704 to 28212)
Kyrgyzstan	6 (0 to 34)	-0.6% (-3 to 0%)	1082 (1061 to 1126)
Tajikistan	4 (0 to 35)	-2.8% (-31.7 to -0.1%)	76 (70 to 111)
Uzbekistan	4746 (912 to 14648)	-52.4% (-68.1 to -37.2%)	8622 (2248 to 24544)
<b>Central Europe</b>	33643 (12584 to 84666)	-55% (-77.7 to -35.8%)	57864 (31281 to 115111)
Albania	1281 (191 to 3257)	-72.6% (-89.2 to -36.4%)	1649 (527 to 3673)
Bosnia and Herzegovina	1706 (283 to 3958)	-58.7% (-77.2 to -29.1%)	2717 (966 to 5302)
Bulgaria	3255 (108 to 11390)	-69.5% (-91.3 to -14.4%)	4108 (760 to 12672)
Croatia	80 (1 to 665)	-12.4% (-75.5 to -0.5%)	282 (189 to 881)
Czechia	3784 (7 to 18324)	-69.9% (-97.3 to -1.6%)	4245 (439 to 18795)
Hungary	1820 (158 to 10666)	-52.6% (-89 to -19.5%)	2614 (803 to 12065)
Montenegro	299 (4 to 712)	-51.5% (-81.1 to -3.3%)	536 (107 to 1283)
North Macedonia	843 (283 to 2577)	-48.9% (-73.1 to -29.4%)	1602 (957 to 3546)
Poland	17603 (4428 to 53995)	-78.8% (-93.5 to -60.4%)	21056 (6870 to 58691)
Romania	2460 (-594 to 5737)	-15% (-29.2 to 2.8%)	17537 (9418 to 28963)
Serbia	188 (8 to 785)	-15.9% (-48.9 to -1.1%)	959 (758 to 1583)
Slovakia	0 (0 to 0)	-0.4% (-0.8 to -0.1%)	36 (34 to 39)
Slovenia	324 (2 to 2580)	-34.7% (-83.9 to -1.6%)	524 (134 to 3298)

Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
<b>Eastern Europe</b>	98371 (49111 to 201686)	-70% (-83.9 to -56.6%)	136682 (84900 to 248375)
Belarus	4125 (362 to 18176)	-71.4% (-94.3 to -33.4%)	5011 (1083 to 19208)
Estonia	50 (1 to 387)	-24% (-83.3 to -1%)	116 (64 to 462)
Latvia	0 (0 to 0)	-0.1% (-0.3 to 0%)	34 (33 to 35)
Lithuania	0 (0 to 0)	-0.1% (-0.4 to 0%)	84 (82 to 90)
Republic of Moldova	1234 (541 to 2597)	-35% (-49.1 to -23.8%)	3440 (2024 to 6095)
Russian Federation	68531 (34249 to 145960)	-71.3% (-85.7 to -57.4%)	93209 (59097 to 170351)
Ukraine	24431 (8090 to 56899)	-68% (-83 to -54.3%)	34789 (13634 to 73926)
<b>High-income</b>	250073 (108951 to 571964)	-24% (-40.2 to -15.1%)	995094 (712918 to 1660553)
<b>Australasia</b>	477 (65 to 1619)	-29.4% (-58.2 to -7.8%)	1387 (812 to 2788)
Australia	477 (65 to 1619)	-29.9% (-58.7 to -8%)	1364 (790 to 2766)
New Zealand	0 (0 to 0)	0% (-0.1 to 0%)	22 (22 to 23)
<b>High-income Asia Pacific</b>	13358 (1388 to 36167)	-14.2% (-22.9 to -3%)	127298 (9560 to 506645)
Japan	13358 (1388 to 36167)	-14.4% (-23.6 to -3%)	126947 (9215 to 506285)
Republic of Korea	0 (0 to 1)	-0.1% (-0.3 to 0%)	324 (316 to 337)
Singapore	0 (0 to 0)	0% (0 to 0%)	27 (27 to 27)
<b>High-income North America</b>	96640 (60284 to 158525)	-23.6% (-34.1 to -16.3%)	404455 (348869 to 486600)
Canada	3145 (370 to 13910)	-15.5% (-37.5 to -3.6%)	16562 (10435 to 41631)
Alberta	1 (0 to 2)	-0.3% (-0.8 to -0.1%)	256 (244 to 275)
British Columbia	0 (0 to 0)	-0.1% (-0.2 to 0%)	203 (199 to 209)
Manitoba	0 (0 to 1)	-1.4% (-3 to -0.3%)	20 (15 to 27)
Nova Scotia	14 (0 to 93)	-10.7% (-48.8 to -0.7%)	84 (65 to 191)
Ontario	421 (69 to 2389)	-9.2% (-37.1 to -2.2%)	3666 (3078 to 6544)
Quebec	2710 (213 to 13540)	-17.4% (-40.7 to -3.2%)	12307 (6612 to 37237)
Saskatchewan	0 (0 to 0)	-0.6% (-1.5 to -0.2%)	26 (24 to 31)
United States of America	93495 (59329 to 150967)	-23.9% (-34.3 to -16.6%)	387893 (335888 to 465041)
Alabama	1178 (137 to 3210)	-28.4% (-51.9 to -5.9%)	3684 (2319 to 6213)
Alaska	1 (0 to 4)	-1.1% (-8.1 to -0.2%)	37 (34 to 50)

Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
Arizona	1723 (727 to 3349)	-19.2% (-29 to -10.6%)	8723 (6723 to 12227)
Arkansas	1458 (116 to 3691)	-43.3% (-64 to -13%)	2999 (908 to 6138)
California	18044 (7422 to 33622)	-32.6% (-44.2 to -21.9%)	54014 (32829 to 84006)
Colorado	1049 (186 to 3797)	-27.3% (-59 to -8.4%)	3288 (2233 to 6371)
Connecticut	255 (53 to 1102)	-4.9% (-18.7 to -1.2%)	4846 (4580 to 5853)
Delaware	138 (14 to 577)	-14.6% (-42.4 to -2.2%)	793 (628 to 1324)
District of Columbia	271 (60 to 745)	-21.9% (-39.6 to -8.1%)	1119 (740 to 2084)
Florida	-1116 (-5457 to 1416)	4.1% (-4.6 to 17.8%)	26485 (16989 to 39801)
Georgia	3126 (1373 to 5395)	-22.4% (-31.8 to -13.6%)	13769 (8994 to 20009)
Hawaii	4 (0 to 8)	-1.7% (-9.2 to -0.3%)	66 (51 to 91)
Idaho	757 (157 to 1922)	-42.9% (-59.4 to -23.8%)	1670 (636 to 3542)
Illinois	6912 (2353 to 17123)	-37% (-58.2 to -20.2%)	17496 (11463 to 30332)
Indiana	3571 (1580 to 8283)	-42.2% (-61.5 to -28.2%)	8059 (5578 to 13589)
Iowa	1158 (406 to 2576)	-31.2% (-45.4 to -18.9%)	3580 (1985 to 6780)
Kansas	1386 (408 to 3868)	-63.9% (-84.1 to -42.6%)	2027 (960 to 4656)
Kentucky	1284 (385 to 2965)	-29.8% (-43.5 to -16.8%)	4299 (1857 to 10252)
Louisiana	2029 (886 to 3158)	-22.3% (-29.9 to -13.1%)	8946 (6638 to 11541)
Maine	109 (11 to 618)	-30% (-75.7 to -7.6%)	263 (147 to 811)
Maryland	1383 (540 to 2822)	-23.7% (-39.5 to -11.8%)	5626 (4566 to 7222)
Massachusetts	2725 (1096 to 6933)	-18.9% (-35.5 to -9.5%)	13788 (11213 to 19579)
Michigan	4550 (1465 to 12387)	-33% (-57.2 to -16.3%)	12758 (8938 to 21972)
Minnesota	2479 (1052 to 5096)	-40.6% (-56.3 to -26.4%)	5888 (3796 to 9798)
Mississippi	1420 (527 to 2386)	-28.3% (-38.6 to -15.5%)	4869 (3372 to 6526)
Missouri	2357 (381 to 6592)	-36.4% (-53.7 to -16.1%)	6020 (2281 to 16923)
Montana	1 (0 to 8)	-1.2% (-6.5 to -0.2%)	107 (96 to 130)
Nebraska	1081 (446 to 2533)	-61% (-79.5 to -44.1%)	1693 (965 to 3241)
Nevada	643 (-150 to 1451)	-14.6% (-26.9 to 2.8%)	4479 (2301 to 7272)
New Hampshire	186 (28 to 659)	-23.9% (-55.4 to -5.8%)	674 (482 to 1230)

Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
New Jersey	407 (80 to 1521)	-2.4% (-8.3 to -0.5%)	16730 (16199 to 18212)
New Mexico	1369 (570 to 2896)	-51.2% (-67.9 to -35.6%)	2577 (1602 to 4385)
New York	1913 (311 to 6275)	-5.2% (-15.5 to -0.9%)	35560 (33519 to 40959)
North Carolina	5472 (1544 to 11963)	-49.9% (-67.3 to -30.3%)	10415 (4927 to 18600)
North Dakota	355 (169 to 733)	-55.1% (-70.8 to -41.4%)	621 (400 to 1055)
Ohio	5620 (2206 to 13363)	-47.1% (-68.1 to -30.4%)	11347 (7296 to 20017)
Oklahoma	1665 (580 to 3646)	-43.6% (-57.7 to -29.9%)	3714 (1794 to 7090)
Oregon	2267 (550 to 6464)	-68.1% (-85.7 to -47%)	3119 (1173 to 7598)
Pennsylvania	6137 (1732 to 19494)	-30.8% (-50.7 to -15.4%)	18168 (11151 to 38785)
Rhode Island	421 (73 to 1592)	-20.5% (-45.1 to -6.1%)	1755 (1194 to 3735)
South Carolina	2279 (905 to 4332)	-34.3% (-46.8 to -21.1%)	6426 (4269 to 9660)
South Dakota	240 (63 to 567)	-48.3% (-69.5 to -24.5%)	463 (256 to 829)
Tennessee	1991 (777 to 3818)	-29.1% (-38.9 to -20.1%)	6757 (3342 to 12108)
Texas	-5057 (-11946 to -860)	16.6% (3 to 38.8%)	30644 (21885 to 40804)
Utah	1370 (414 to 3312)	-64.5% (-83.1 to -44.9%)	1998 (916 to 4211)
Vermont	3 (0 to 21)	-4.1% (-25.4 to 0%)	62 (58 to 83)
Virginia	780 (28 to 2603)	-17.3% (-41.5 to -1.1%)	3777 (2574 to 6416)
Washington	3164 (1216 to 6444)	-44.7% (-61.2 to -30.3%)	6863 (3864 to 12327)
West Virginia	282 (43 to 890)	-41.3% (-69.4 to -15.4%)	584 (279 to 1315)
Wisconsin	2658 (480 to 7754)	-56.9% (-81.4 to -27.3%)	4213 (1747 to 9555)
Wyoming	0 (0 to 0)	-0.3% (-0.5 to -0.2%)	34 (32 to 36)
<b>Southern Latin America</b>	2096 (885 to 3789)	-5.2% (-7.9 to -2.9%)	39535 (29734 to 49870)
Argentina	1998 (798 to 3724)	-7.8% (-11.1 to -4.9%)	24972 (15882 to 35043)
Chile	98 (46 to 194)	-0.7% (-1.2 to -0.3%)	14513 (12932 to 16643)
Uruguay	0 (0 to 0)	-0.2% (-0.6 to -0.1%)	50 (46 to 58)
<b>Western Europe</b>	137502 (34764 to 400664)	-29.1% (-52.4 to -12.9%)	422419 (265320 to 786956)
Andorra	32 (1 to 160)	-24% (-62.2 to -2.2%)	97 (56 to 270)
Austria	4262 (523 to 22283)	-70.9% (-95.5 to -39.6%)	5130 (1303 to 23275)

Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
Belgium	2951 (420 to 9818)	-12.3% (-25 to -3.4%)	21299 (12103 to 53485)
Cyprus	0 (0 to 0)	-0.1% (-0.2 to 0%)	21 (20 to 21)
Denmark	844 (111 to 4271)	-42.9% (-85.9 to -14.3%)	1530 (777 to 4973)
Finland	2488 (52 to 15439)	-62.8% (-97.6 to -13.2%)	2846 (393 to 15840)
France	26193 (4775 to 123424)	-29.7% (-61.9 to -11.4%)	72074 (41454 to 207948)
Germany	35016 (5447 to 133085)	-58.5% (-83.8 to -31.8%)	52402 (16961 to 176009)
Baden-Wuerttemberg	4735 (215 to 32693)	-40.6% (-88 to -9.5%)	7278 (2266 to 37786)
Bavaria	7705 (287 to 52186)	-38.7% (-73.6 to -8.6%)	14073 (3300 to 77704)
Berlin	1293 (2 to 13290)	-34.9% (-94.4 to -0.8%)	1596 (226 to 13983)
Brandenburg	96 (5 to 490)	-25.4% (-72.4 to -3%)	271 (174 to 677)
Bremen	40 (0 to 299)	-21.3% (-81.6 to -0.8%)	98 (56 to 372)
Hamburg	1183 (63 to 4921)	-39.2% (-63.2 to -14.4%)	2789 (409 to 13787)
Hesse	674 (63 to 3228)	-41.5% (-82.6 to -10.4%)	1255 (603 to 3847)
Lower Saxony	377 (20 to 2420)	-23.5% (-73.8 to -2.9%)	1071 (681 to 3279)
Mecklenburg-Vorpommern	0 (0 to 0)	0% (0 to 0%)	20 (20 to 20)
North Rhine-Westphalia	12592 (1985 to 52956)	-70.4% (-92.1 to -45.2%)	15781 (4319 to 57544)
Rhineland-Palatinate	2175 (65 to 16503)	-61.9% (-94.2 to -19.9%)	2588 (323 to 17724)
Saarland	434 (3 to 4258)	-28.1% (-75.4 to -1.4%)	796 (188 to 6016)
Saxony	2119 (2 to 19528)	-43.8% (-93 to -1.1%)	2642 (228 to 21613)
Saxony-Anhalt	0 (0 to 0)	-0.1% (-0.1 to 0%)	65 (64 to 66)
Schleswig-Holstein	581 (2 to 3027)	-55.3% (-91.3 to -0.9%)	781 (161 to 3315)
Thuringia	1013 (15 to 8697)	-49.5% (-92.3 to -7.2%)	1299 (209 to 9388)
Greece	307 (7 to 1523)	-33.2% (-81.7 to -2.3%)	615 (292 to 1859)
Iceland	0 (0 to 0)	0% (0 to 0%)	11 (11 to 11)
Ireland	442 (114 to 1583)	-15.5% (-41.2 to -5.5%)	2502 (2073 to 3889)
Israel	318 (-424 to 911)	-4.8% (-11.5 to 4.6%)	7259 (4198 to 12909)
Italy	11414 (2840 to 43608)	-18.8% (-46.2 to -6.8%)	53593 (41492 to 93274)
Abruzzo	29 (6 to 103)	-5% (-15.6 to -1.2%)	548 (507 to 656)

Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
Basilicata	0 (0 to 0)	0% (0 to 0%)	28 (28 to 28)
Calabria	12 (0 to 54)	-9.3% (-35.3 to -0.4%)	109 (96 to 153)
Campania	180 (3 to 1109)	-17.7% (-67.4 to -0.6%)	643 (442 to 1626)
Emilia-Romagna	524 (183 to 1545)	-9.3% (-23.4 to -3.7%)	5379 (4934 to 6581)
Friuli-Venezia Giulia	452 (9 to 3052)	-22.4% (-52.6 to -2.4%)	1348 (388 to 7194)
Lazio	2157 (213 to 12406)	-38.9% (-68.1 to -15.4%)	4301 (1374 to 20065)
Liguria	184 (69 to 567)	-9.3% (-24 to -3.9%)	1903 (1750 to 2406)
Lombardia	1630 (312 to 7450)	-7.3% (-27.8 to -1.8%)	19525 (17681 to 26987)
Marche	400 (33 to 1999)	-13.4% (-32.4 to -2.8%)	2357 (1153 to 8319)
Molise	24 (0 to 178)	-25.6% (-83 to -1.3%)	49 (24 to 206)
Piemonte	743 (215 to 2604)	-12.7% (-34.3 to -4.6%)	5319 (4656 to 7605)
Provincia autonoma di Bolzano	451 (28 to 1549)	-29.9% (-51.5 to -7.6%)	1294 (368 to 4953)
Provincia autonoma di Trento	201 (15 to 1306)	-20% (-63.7 to -3.3%)	693 (449 to 2007)
Puglia	60 (17 to 159)	-8.5% (-19.7 to -2.8%)	680 (617 to 810)
Sardegna	171 (1 to 1246)	-23% (-84.7 to -0.5%)	320 (134 to 1444)
Sicilia	2513 (32 to 23857)	-55.5% (-92.5 to -9.8%)	3053 (326 to 25558)
Toscana	188 (42 to 833)	-11.3% (-37.6 to -3.3%)	1452 (1254 to 2215)
Umbria	59 (1 to 431)	-20.9% (-77 to -1%)	146 (80 to 564)
Valle d'Aosta	10 (-17 to 46)	-4.6% (-13.9 to 3.6%)	232 (160 to 541)
Veneto	1424 (438 to 4813)	-30.2% (-59.1 to -14.5%)	4214 (3018 to 8085)
Luxembourg	222 (2 to 1798)	-32.2% (-79.7 to -1.5%)	410 (131 to 2217)
Malta	0 (0 to 0)	-0.2% (-0.7 to 0%)	11 (10 to 12)
Netherlands	23283 (2449 to 70697)	-55.2% (-77 to -23.8%)	37734 (10128 to 112518)
Norway	1 (0 to 3)	-0.3% (-0.9 to -0.1%)	273 (269 to 283)
Portugal	4040 (842 to 16130)	-40.6% (-63.7 to -22.2%)	8625 (3616 to 26575)
San Marino	2 (1 to 6)	-4% (-12.5 to -1.3%)	46 (44 to 51)
Spain	2172 (842 to 4217)	-3.4% (-5 to -2%)	62759 (40401 to 114006)
Andalucia	233 (9 to 943)	-3.2% (-7.3 to -0.5%)	7248 (1728 to 30953)

Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
Aragon	304 (32 to 568)	-8.7% (-13.5 to -2%)	3309 (1515 to 5909)
Asturias	108 (3 to 357)	-6.1% (-13.1 to -0.8%)	1622 (368 to 6480)
Balearic Islands	41 (0 to 237)	-3.5% (-10.3 to -0.1%)	820 (242 to 5117)
Basque Country	62 (10 to 177)	-1.8% (-3.8 to -0.5%)	3233 (1888 to 7052)
Canary Islands	88 (1 to 672)	-10.8% (-32.6 to -0.6%)	456 (182 to 2132)
Cantabria	3 (-14 to 20)	-0.8% (-2.6 to 1.4%)	526 (260 to 1404)
Castile and Leon	49 (-8 to 137)	-1.3% (-2.9 to 0.2%)	3825 (2493 to 7854)
Castilla-La Mancha	76 (11 to 238)	-1.5% (-3.6 to -0.3%)	4438 (3274 to 9137)
Catalonia	140 (-16 to 556)	-1.3% (-3.7 to 0.1%)	10137 (6343 to 29466)
Community of Madrid	543 (114 to 1101)	-3.3% (-5.5 to -1%)	15711 (11045 to 25243)
Extremadura	139 (22 to 305)	-7.2% (-11.1 to -2.8%)	1840 (735 to 5117)
Galicia	289 (18 to 562)	-5.4% (-8.6 to -1.2%)	6021 (895 to 16290)
La Rioja	42 (3 to 90)	-4.4% (-8.3 to -0.7%)	876 (399 to 2053)
Murcia	24 (1 to 287)	-3.7% (-22.4 to -0.3%)	255 (162 to 1135)
Navarre	24 (2 to 113)	-2.2% (-6.2 to -0.3%)	883 (574 to 2814)
Valencian Community	7 (1 to 22)	-0.4% (-1.3 to -0.1%)	1558 (1514 to 1642)
Sweden	5877 (723 to 33748)	-34.7% (-80.9 to -10.3%)	12630 (7010 to 43042)
Switzerland	6062 (523 to 29072)	-55.7% (-91 to -19.4%)	8494 (2693 to 32047)
United Kingdom	11576 (2407 to 41847)	-14.4% (-39.2 to -4%)	72058 (59867 to 109943)
England	6788 (836 to 32436)	-10.5% (-38.5 to -1.7%)	57268 (50309 to 83352)
Northern Ireland	513 (14 to 2526)	-18% (-48.9 to -1.6%)	2035 (899 to 8106)
Scotland	2183 (114 to 10057)	-20.5% (-51.4 to -2.6%)	7953 (4417 to 23462)
Wales	2093 (423 to 9185)	-36.5% (-74.8 to -13.8%)	4803 (3051 to 12082)
<b>Latin America and Caribbean</b>	<b>37504 (25393 to 53623)</b>	<b>-7.2% (-9.9 to -5%)</b>	<b>516699 (480313 to 573553)</b>
<b>Andean Latin America</b>	<b>770 (551 to 979)</b>	<b>-1% (-1.3 to -0.8%)</b>	<b>74343 (71361 to 77374)</b>
Bolivia (Plurinational State of)	300 (147 to 463)	-4.2% (-5.8 to -2.4%)	7029 (6055 to 8255)
Ecuador	296 (217 to 367)	-1.4% (-1.7 to -1%)	21830 (20856 to 22758)
Peru	174 (108 to 258)	-0.4% (-0.6 to -0.2%)	45484 (43143 to 47828)



Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
Caribbean	2837 (224 to 8748)	-15.2% (-37.7 to -1.9%)	16272 (7722 to 30615)
Bahamas	3 (0 to 31)	-2% (-12.5 to -0.1%)	83 (42 to 254)
Barbados	0 (0 to 0)	0% (0 to 0%)	8 (8 to 8)
Belize	8 (0 to 62)	-4.1% (-37.3 to -0.1%)	107 (12 to 769)
Cuba	0 (0 to 0)	0% (0 to 0%)	91 (89 to 94)
Dominican Republic	162 (-30 to 356)	-2.2% (-4.4 to 0.3%)	8068 (3761 to 14541)
Guyana	20 (0 to 85)	-5.6% (-22.2 to 0%)	263 (35 to 1350)
Haiti	2536 (9 to 8390)	-65.3% (-91 to -4.3%)	3315 (222 to 11298)
Jamaica	43 (0 to 441)	-3.7% (-33.6 to 0%)	324 (17 to 3744)
Puerto Rico	52 (13 to 91)	-1.6% (-2.5 to -0.9%)	3448 (912 to 7194)
Suriname	4 (-9 to 10)	-1.3% (-4.1 to 1.1%)	458 (147 to 961)
Trinidad and Tobago	3 (0 to 35)	-1.3% (-14.7 to 0%)	40 (21 to 115)
United States Virgin Islands	5 (0 to 22)	-6.7% (-15.8 to 0%)	68 (11 to 350)
<b>Central Latin America</b>	10228 (4278 to 20014)	-4.4% (-8.1 to -1.8%)	230480 (200713 to 277348)
Colombia	-5432 (-9115 to -3011)	10.8% (6.6 to 16.9%)	50114 (41136 to 59430)
Costa Rica	213 (80 to 405)	-6.8% (-12.4 to -1.8%)	3573 (1229 to 7714)
El Salvador	296 (104 to 620)	-8.2% (-14 to -4.1%)	3756 (1438 to 8258)
Guatemala	365 (139 to 737)	-4.7% (-7.3 to -2.8%)	7500 (4493 to 11832)
Honduras	339 (6 to 1100)	-8.8% (-19.9 to -0.3%)	3250 (1719 to 6566)
Mexico	11813 (7537 to 17383)	-8.2% (-12.1 to -5.5%)	143326 (126904 to 163923)
Aguascalientes	249 (165 to 378)	-17.5% (-28.5 to -10.3%)	1454 (988 to 1854)
Baja California	136 (24 to 243)	-2.4% (-4.3 to -0.4%)	5688 (4567 to 6842)
Baja California Sur	59 (17 to 96)	-7.8% (-12 to -3.4%)	751 (445 to 1111)
Campeche	50 (19 to 79)	-3.5% (-5.4 to -1.9%)	1422 (926 to 1822)
Chiapas	201 (40 to 688)	-12.1% (-29.9 to -3.5%)	1461 (1128 to 2388)
Chihuahua	114 (-101 to 280)	-3.6% (-8.3 to 2.2%)	3412 (2089 to 4950)
Coahuila	-22 (-210 to 90)	0.4% (-3 to 4.9%)	3547 (2010 to 4973)
Colima	123 (60 to 177)	-11.8% (-17.2 to -7.6%)	1058 (626 to 1485)

Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
Durango	368 (20 to 814)	-24.4% (-38.1 to -4.4%)	1384 (464 to 2828)
Guanajuato	1292 (79 to 2490)	-21.5% (-35.7 to -4.3%)	5806 (1819 to 11217)
Guerrero	332 (101 to 624)	-8% (-13.9 to -1.9%)	4258 (2848 to 6945)
Hidalgo	-303 (-688 to -54)	7.9% (1.3 to 17.8%)	3839 (2994 to 4716)
Jalisco	1164 (480 to 1915)	-15.2% (-23.1 to -9.2%)	7685 (4015 to 12106)
Mexico	3193 (1835 to 4891)	-16.6% (-22.9 to -11.8%)	19063 (14149 to 25313)
Mexico City	253 (-188 to 556)	-1.5% (-3.4 to 1%)	17385 (15277 to 20112)
Michoacan de Ocampo	255 (66 to 447)	-5.8% (-10.3 to -1.1%)	4615 (2838 to 6901)
Morelos	-101 (-391 to 72)	4.3% (-2.6 to 14.8%)	2367 (1417 to 3828)
Nayarit	96 (-9 to 203)	-6.3% (-12.4 to 0.6%)	1540 (935 to 2272)
Nuevo Leon	-19 (-239 to 142)	0.2% (-2.4 to 3.3%)	6202 (3850 to 8277)
Oaxaca	585 (316 to 907)	-14.8% (-21.5 to -9.5%)	3961 (2524 to 5680)
Puebla	580 (315 to 895)	-7.2% (-11.2 to -3.8%)	8202 (5675 to 10584)
Queretaro	115 (7 to 222)	-5.4% (-10.1 to -0.3%)	2212 (1251 to 3357)
Quintana Roo	-1 (-59 to 37)	0% (-1.4 to 2.1%)	2776 (2413 to 3213)
San Luis Potosi	117 (-59 to 254)	-4.1% (-8.5 to 1.4%)	3152 (1543 to 4610)
Sinaloa	464 (105 to 906)	-10.7% (-17.5 to -3.4%)	4158 (3082 to 5636)
Sonora	113 (3 to 434)	-3.4% (-10.5 to -0.1%)	2987 (2551 to 4237)
Tabasco	196 (134 to 268)	-5% (-6.6 to -3.6%)	3915 (3461 to 4405)
Tamaulipas	168 (18 to 354)	-4.3% (-9.3 to -0.7%)	4159 (2110 to 6819)
Tlaxcala	212 (124 to 322)	-12.5% (-17.6 to -8.4%)	1691 (1302 to 2129)
Veracruz de Ignacio de la Llave	1436 (672 to 2519)	-15.9% (-22.6 to -10.5%)	8908 (6002 to 12896)
Yucatan	15 (-24 to 42)	-0.5% (-1.5 to 0.7%)	2971 (2018 to 3895)
Zacatecas	372 (66 to 787)	-26.9% (-40.9 to -11.1%)	1297 (605 to 2307)
Nicaragua	753 (187 to 2822)	-59.5% (-81.5 to -39.6%)	1156 (419 to 3664)
Panama	80 (44 to 132)	-1.7% (-2.7 to -1%)	4642 (3566 to 5919)
Venezuela (Bolivarian Republic of)	1802 (306 to 4744)	-14.5% (-22.7 to -8.8%)	13163 (2198 to 42916)
<b>Tropical Latin America</b>	<b>23670 (16514 to 32318)</b>	<b>-12.1% (-15.1 to -9.1%)</b>	<b>195605 (177261 to 216305)</b>

Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
Brazil	22980 (16107 to 31013)	-11.9% (-14.9 to -9.1%)	192567 (172939 to 213949)
Acre	30 (9 to 59)	-4% (-7.1 to -1.4%)	729 (656 to 830)
Alagoas	143 (82 to 216)	-6% (-8.4 to -3.8%)	2355 (2179 to 2569)
Amapa	70 (26 to 126)	-8.4% (-13.7 to -3.6%)	819 (719 to 932)
Amazonas	689 (277 to 1344)	-12.5% (-20.5 to -6.4%)	5340 (4291 to 6750)
Bahia	3701 (2163 to 5740)	-23.1% (-30.5 to -16%)	15826 (12202 to 20682)
Ceara	252 (86 to 578)	-2.6% (-5.6 to -1%)	9386 (8799 to 10382)
Distrito Federal	85 (56 to 126)	-2.2% (-3 to -1.6%)	3872 (3330 to 4509)
Espirito Santo	513 (326 to 772)	-10.9% (-14.5 to -7.9%)	4659 (4059 to 5429)
Goias	1054 (300 to 1712)	-15% (-21.3 to -7.7%)	6888 (3846 to 10016)
Maranhao	120 (60 to 223)	-3.1% (-5.3 to -1.6%)	3870 (3685 to 4137)
Mato Grosso	208 (110 to 330)	-5.6% (-7.9 to -3.4%)	3656 (3217 to 4392)
Mato Grosso do Sul	379 (197 to 600)	-19% (-25 to -13.1%)	1971 (1444 to 2668)
Minas Gerais	4156 (1787 to 7668)	-26.3% (-35.1 to -17.5%)	15470 (9735 to 23790)
Para	306 (59 to 889)	-4.2% (-10.9 to -0.9%)	7002 (6314 to 8226)
Paraiba	473 (267 to 887)	-11.7% (-17.8 to -8.1%)	3975 (3313 to 5110)
Parana	711 (269 to 1448)	-12% (-18.3 to -6.1%)	5686 (4357 to 8096)
Pernambuco	1081 (575 to 1983)	-10.3% (-16.3 to -6.2%)	10358 (9119 to 12465)
Piaui	212 (76 to 372)	-8.4% (-13 to -3.7%)	2451 (2064 to 2919)
Rio de Janeiro	2573 (566 to 5619)	-10% (-17.6 to -3.3%)	24472 (17382 to 34146)
Rio Grande do Norte	163 (17 to 444)	-5.7% (-12.7 to -0.7%)	2701 (2264 to 3492)
Rio Grande do Sul	1071 (255 to 2297)	-15.6% (-24.9 to -6%)	6485 (4277 to 9733)
Rondonia	82 (33 to 156)	-5.5% (-9.2 to -2.6%)	1453 (1257 to 1769)
Roraima	35 (7 to 65)	-4.9% (-8.3 to -1.2%)	707 (625 to 804)
Santa Catarina	835 (210 to 1788)	-16.1% (-25.5 to -6.8%)	4887 (3075 to 7767)
Sao Paulo	3721 (1565 to 6722)	-8.3% (-12.8 to -4.4%)	43949 (35894 to 56669)
Sergipe	78 (36 to 123)	-3.4% (-5 to -1.8%)	2238 (2051 to 2500)
Tocantins	240 (95 to 385)	-17.3% (-22.7 to -10.6%)	1365 (886 to 1885)

Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
Paraguay	690 (149 to 1616)	-23.1% (-34.5 to -13.5%)	3038 (902 to 8437)
<b>North Africa and Middle East</b>	124534 (70240 to 225566)	-48.1% (-60.5 to -37.6%)	253851 (177663 to 398457)
Afghanistan	4415 (125 to 21891)	-45.9% (-86.8 to -7.8%)	6643 (1596 to 29983)
Algeria	11791 (3936 to 30808)	-78.4% (-92.2 to -61.9%)	14313 (6230 to 33896)
Bahrain	369 (149 to 806)	-52.4% (-70.9 to -35.3%)	672 (411 to 1193)
Egypt	4910 (1868 to 16575)	-41.5% (-72.4 to -24.5%)	10803 (7569 to 22541)
Iran (Islamic Republic of)	35201 (20644 to 63386)	-49.2% (-62.4 to -37.7%)	70238 (52788 to 103293)
Iraq	15293 (9647 to 22648)	-46.9% (-57.7 to -37%)	32454 (24889 to 45236)
Jordan	448 (0 to 9494)	-6.7% (-98.3 to 0%)	497 (12 to 9530)
Kuwait	354 (107 to 801)	-29.8% (-47.4 to -14.3%)	1117 (732 to 1763)
Lebanon	221 (20 to 733)	-38.8% (-69.7 to -8.9%)	471 (222 to 1095)
Libya	3678 (1320 to 6985)	-76.7% (-88 to -62.5%)	4789 (1753 to 9222)
Morocco	4642 (-1692 to 9591)	-21.1% (-39.4 to 4%)	25438 (11257 to 46725)
Oman	501 (332 to 748)	-15.8% (-26.2 to -8.1%)	3302 (2035 to 4788)
Palestine	1853 (820 to 3022)	-61.2% (-81.2 to -29.2%)	3225 (1219 to 6136)
Qatar	302 (0 to 1205)	-24.9% (-62.3 to 0%)	716 (196 to 2324)
Saudi Arabia	7691 (4241 to 12879)	-38.6% (-50.7 to -28.2%)	19591 (14083 to 27591)
Sudan	3444 (717 to 11761)	-69.8% (-92 to -43.9%)	4448 (1653 to 12853)
Syrian Arab Republic	1455 (-1737 to 4381)	-28.4% (-57.5 to 8.8%)	8355 (1003 to 28240)
Tunisia	3547 (6 to 24378)	-70.5% (-98.8 to -6.2%)	3729 (105 to 24591)
Turkey	23128 (7823 to 57393)	-56.9% (-75.8 to -38.7%)	37993 (19853 to 78767)
United Arab Emirates	1005 (250 to 2349)	-27.2% (-44.4 to -10.3%)	4152 (1070 to 11276)
Yemen	288 (27 to 1383)	-24.8% (-67.8 to -4.4%)	906 (617 to 2041)
<b>South Asia</b>	216549 (100735 to 392702)	-27% (-35.8 to -18.9%)	794413 (484774 to 1325944)
Bangladesh	43206 (14774 to 98187)	-71.1% (-83.9 to -55.3%)	58297 (25558 to 121943)
India	158832 (75152 to 282838)	-22.5% (-30.7 to -14.9%)	703364 (431127 to 1173219)
Andhra Pradesh	2379 (-1672 to 4927)	-7.2% (-16.2 to 3.4%)	36635 (23600 to 54621)
Arunachal Pradesh	300 (0 to 1325)	-40.6% (-98.9 to -0.4%)	492 (8 to 1735)

Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
Assam	5248 (2212 to 9030)	-30.9% (-49.5 to -8.3%)	19529 (6619 to 37744)
Bihar	24344 (1648 to 74027)	-72.4% (-87.6 to -54.8%)	32362 (2913 to 100770)
Chhattisgarh	2538 (213 to 4418)	-17.3% (-33.6 to -0.7%)	18305 (6076 to 34827)
Delhi	2299 (945 to 5317)	-25.7% (-40.3 to -15%)	8522 (6051 to 14860)
Goa	297 (199 to 390)	-19.5% (-28 to -10.4%)	1563 (1061 to 2029)
Gujarat	5945 (1814 to 17281)	-41.5% (-60.9 to -25.6%)	13314 (6658 to 29470)
Haryana	5260 (2419 to 9633)	-35.8% (-49 to -21.7%)	15107 (7050 to 28373)
Himachal Pradesh	1635 (44 to 6071)	-60% (-80.3 to -31.3%)	2581 (140 to 10776)
Jammu & Kashmir and Ladakh	3392 (1796 to 5393)	-43.8% (-58.6 to -32%)	7782 (4469 to 12519)
Jharkhand	3878 (1597 to 6240)	-23.3% (-40.3 to -5.5%)	19114 (5975 to 34217)
Karnataka	107 (-4501 to 2826)	-0.7% (-7.3 to 8%)	45119 (27297 to 68596)
Kerala	1351 (97 to 2712)	-8.2% (-15 to -0.2%)	21021 (6293 to 50017)
Madhya Pradesh	22319 (6449 to 47305)	-58.7% (-73.5 to -46.4%)	37537 (12689 to 83736)
Maharashtra	143 (-6264 to 4200)	-0.4% (-4.9 to 5.2%)	100542 (77736 to 129249)
Manipur	933 (234 to 1745)	-43.5% (-78.5 to -5.1%)	2621 (723 to 4765)
Meghalaya	168 (0 to 1078)	-8.1% (-58.1 to -0.1%)	771 (8 to 3612)
Nagaland	0 (0 to 0)	-0.2% (-0.4 to -0.1%)	8 (8 to 9)
Odisha	5463 (2020 to 9416)	-23.3% (-38 to -4.2%)	27328 (9552 to 54951)
Punjab	1386 (-913 to 2787)	-7.5% (-17 to 3%)	21415 (11810 to 33224)
Rajasthan	12962 (3658 to 35725)	-66.1% (-81.3 to -49.4%)	18581 (6866 to 46819)
Tamil Nadu	8089 (2076 to 15881)	-14.4% (-24.6 to -2.6%)	59039 (31558 to 98024)
Telangana	3694 (666 to 11479)	-52.9% (-73.2 to -32.5%)	6405 (1913 to 16536)
Tripura	815 (485 to 1121)	-23.7% (-43.1 to -9.4%)	3733 (2188 to 5269)
Uttar Pradesh	36143 (16879 to 62750)	-33.1% (-47.5 to -14.3%)	116309 (48420 to 215109)
Uttarakhand	720 (60 to 1329)	-14.3% (-32.3 to -0.6%)	6737 (986 to 13967)
West Bengal	7022 (-19 to 12481)	-13.2% (-24.2 to 0%)	60895 (29712 to 107570)
Nepal	5341 (1607 to 10032)	-41% (-65.8 to -11%)	15455 (3199 to 33368)
Pakistan	9170 (2600 to 32238)	-47.5% (-73.8 to -27%)	17297 (9490 to 45445)

Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
Azad Jammu & Kashmir	1312 (0 to 3255)	-66.2% (-96.6 to -0.5%)	1781 (64 to 4302)
Balochistan	884 (0 to 5894)	-49.6% (-94.6 to -0.3%)	1091 (141 to 6891)
Gilgit-Baltistan	349 (72 to 912)	-72.9% (-89.7 to -46.9%)	451 (152 to 1054)
Islamabad Capital Territory	503 (233 to 776)	-49.8% (-66.8 to -25.3%)	1038 (516 to 1633)
Khyber Pakhtunkhwa	215 (27 to 920)	-12.4% (-40 to -2.1%)	1510 (1298 to 2373)
Punjab	479 (51 to 2398)	-14% (-50.1 to -2.2%)	2728 (2265 to 4628)
Sindh	5428 (975 to 23812)	-52.6% (-83.4 to -26.4%)	8697 (3709 to 31172)
<b>Southeast Asia, East Asia, and Oceania</b>	5600 (1897 to 11136)	-6.6% (-14.4 to -1.3%)	95856 (43874 to 175366)
<b>East Asia</b>	2119 (1 to 6399)	-20.2% (-66.6 to -0.8%)	16367 (173 to 45930)
China	2118 (0 to 6398)	-20.1% (-66.7 to -0.2%)	16357 (164 to 45920)
Beijing	0 (0 to 0)	0% (-0.1 to 0%)	10 (10 to 10)
Chongqing	0 (0 to 0)	0% (-0.1 to 0%)	7 (6 to 7)
Guangdong	0 (0 to 0)	-0.1% (-0.1 to 0%)	10 (10 to 10)
Hainan	0 (0 to 0)	0% (-0.1 to 0%)	7 (7 to 7)
Hebei	0 (0 to 0)	0% (-0.1 to 0%)	7 (7 to 7)
Heilongjiang	0 (0 to 0)	0% (0 to 0%)	15 (14 to 15)
Hong Kong Special Administrative Region of China	2118 (0 to 6398)	-20.8% (-70.7 to -0.2%)	16286 (92 to 45848)
Shandong	0 (0 to 0)	-0.1% (-0.1 to 0%)	9 (9 to 9)
Shanghai	0 (0 to 0)	-0.1% (-0.1 to 0%)	8 (8 to 8)
Taiwan (Province of China)	2 (0 to 5)	-15.3% (-35.7 to -5.7%)	9 (8 to 13)
Oceania	0 (0 to 1)	-1.1% (-5.9 to 0%)	9 (7 to 14)
Guam	0 (0 to 1)	-1.1% (-5.9 to 0%)	9 (7 to 14)
<b>Southeast Asia</b>	3480 (410 to 6914)	-5.2% (-12.6 to -0.3%)	79480 (40114 to 139194)
Indonesia	3238 (1690 to 6213)	-20.6% (-30.9 to -13.9%)	15271 (11804 to 20779)
Malaysia	0 (0 to 0)	0% (0 to 0%)	123 (123 to 124)
Maldives	97 (34 to 171)	-47.1% (-69.2 to -26.4%)	214 (80 to 385)
Mauritius	0 (0 to 0)	0% (0 to 0%)	11 (11 to 11)
Myanmar	0 (0 to 0)	-0.1% (-0.2 to 0%)	7 (7 to 7)

Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
Philippines	145 (-2641 to 1689)	-0.8% (-4.4 to 2.6%)	63785 (23465 to 125601)
Sri Lanka	0 (0 to 0)	-0.1% (-0.3 to 0%)	12 (11 to 13)
Thailand	0 (0 to 0)	0% (0 to 0%)	57 (57 to 58)
<b>Sub-Saharan Africa</b>	46883 (19950 to 88259)	-40.1% (-53.9 to -28.4%)	115886 (58348 to 198596)
<b>Central Sub-Saharan Africa</b>	677 (183 to 1735)	-37.2% (-59.7 to -19.1%)	1705 (966 to 2926)
Angola	48 (7 to 136)	-19.6% (-38.2 to -5.1%)	219 (135 to 381)
Central African Republic	0 (0 to 0)	0% (-0.1 to 0%)	61 (60 to 61)
Congo	135 (1 to 704)	-31.1% (-71.8 to -0.8%)	286 (93 to 1033)
Democratic Republic of the Congo	246 (70 to 723)	-38.1% (-66.7 to -18.8%)	581 (368 to 1114)
Equatorial Guinea	248 (19 to 476)	-47.3% (-66.8 to -15.4%)	501 (125 to 940)
Gabon	0 (0 to 1)	-0.2% (-0.8 to 0%)	56 (55 to 60)
<b>Eastern Sub-Saharan Africa</b>	36329 (14053 to 69160)	-48% (-66.1 to -30.6%)	78765 (27000 to 151857)
Comoros	0 (0 to 0)	0% (-0.1 to 0%)	7 (7 to 7)
Djibouti	0 (0 to 0)	0% (0 to 0%)	59 (59 to 60)
Ethiopia	28639 (9671 to 51209)	-60.6% (-78.8 to -40%)	48905 (16095 to 92152)
Kenya	2700 (100 to 10740)	-52.7% (-77.9 to -13.4%)	4355 (766 to 14289)
Madagascar	290 (8 to 1413)	-23.6% (-46 to -3.4%)	939 (229 to 3487)
Malawi	128 (3 to 516)	-25.9% (-59.4 to -1.7%)	381 (196 to 869)
Mozambique	3 (0 to 27)	-8.8% (-46.4 to -0.5%)	28 (22 to 57)
Rwanda	1074 (11 to 6945)	-66.4% (-88.5 to -24.7%)	1473 (42 to 10664)
Somalia	0 (0 to 0)	0% (0 to 0%)	92 (92 to 92)
South Sudan	0 (0 to 0)	0% (0 to 0%)	47 (46 to 47)
Uganda	-108 (-5317 to 2423)	-5.1% (-35 to 23.1%)	17925 (1519 to 43838)
United Republic of Tanzania	3569 (832 to 11986)	-80.4% (-94.4 to -63.4%)	4182 (1312 to 12706)
Zambia	32 (0 to 113)	-7.5% (-20.8 to -0.1%)	373 (281 to 545)
<b>Southern Sub-Saharan Africa</b>	1935 (766 to 3645)	-8.2% (-13 to -4.2%)	22913 (18441 to 28851)
Eswatini	67 (26 to 119)	-19.3% (-26.6 to -12.5%)	337 (199 to 502)
Lesotho	145 (1 to 473)	-26.9% (-48.2 to -1.3%)	447 (43 to 1546)

Location	Lives saved (95% UI)	Percent difference in deaths (95% UI)	Cumulative deaths in reference scenario (95% UI)
Namibia	290 (79 to 545)	-30.3% (-43.8 to -19.9%)	987 (297 to 2073)
South Africa	1360 (434 to 2792)	-6.3% (-11 to -2.5%)	20680 (16918 to 25940)
Zimbabwe	73 (5 to 287)	-13% (-25.9 to -2.4%)	461 (220 to 1137)
<b>Western Sub-Saharan Africa</b>	<b>7941 (2767 to 21231)</b>	<b>-59.6% (-80.7 to -40.3%)</b>	<b>12504 (6801 to 26726)</b>
Benin	0 (0 to 0)	-0.1% (-0.3 to 0%)	41 (40 to 42)
Burkina Faso	0 (0 to 1)	-0.2% (-1 to -0.1%)	59 (58 to 61)
Cabo Verde	204 (0 to 615)	-47.1% (-91 to -0.5%)	331 (42 to 898)
Cameroon	149 (7 to 709)	-21% (-59.4 to -1.6%)	588 (426 to 1183)
Chad	0 (0 to 0)	0% (-0.1 to 0%)	74 (74 to 75)
Cote d'Ivoire	431 (69 to 1811)	-65.5% (-91 to -34.7%)	578 (197 to 1948)
Gambia	527 (111 to 1007)	-51.9% (-71.8 to -28.9%)	985 (342 to 1767)
Ghana	3168 (148 to 13458)	-70.4% (-91 to -32.3%)	3994 (469 to 15532)
Guinea	1261 (0 to 7123)	-71.9% (-98.3 to -0.3%)	1370 (57 to 7761)
Guinea-Bissau	297 (2 to 1158)	-54.6% (-90.8 to -4.1%)	396 (49 to 1498)
Liberia	26 (0 to 394)	-5.6% (-80 to 0%)	109 (80 to 483)
Mali	0 (0 to 0)	0% (-0.1 to 0%)	128 (127 to 130)
Mauritania	0 (0 to 0)	0% (0 to 0%)	157 (157 to 158)
Niger	0 (0 to 0)	0% (0 to 0%)	70 (69 to 70)
Nigeria	471 (140 to 1001)	-28% (-45.6 to -11.4%)	1608 (1214 to 2233)
Sao Tome and Principe	10 (0 to 80)	-21.4% (-78.2 to -0.2%)	26 (15 to 100)
Senegal	1239 (284 to 4326)	-65.6% (-87.3 to -42.9%)	1723 (634 to 5065)
Sierra Leone	0 (0 to 0)	-0.1% (-0.1 to 0%)	69 (69 to 70)
Togo	158 (0 to 1242)	-39.2% (-94.4 to -0.1%)	199 (27 to 1362)



## References

- 1 Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *The Lancet Infectious Diseases* 2020; **20**: 533–4.
- 2 World Health Organization. Advice on the use of masks in the context of COVID-19: Interim guidance. Geneva, Switzerland, 2020 [https://apps.who.int/iris/bitstream/handle/10665/331693/WHO-2019-nCov-IPC\\_Masks-2020.3-eng.pdf?sequence=1&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/331693/WHO-2019-nCov-IPC_Masks-2020.3-eng.pdf?sequence=1&isAllowed=y).
- 3 Greenhalgh T, Schmid MB, Czypionka T, Bassler D, Gruer L. Face masks for the public during the covid-19 crisis. *BMJ* 2020; **369**. DOI:10.1136/bmj.m1435.
- 4 Liang M, Gao L, Cheng C, *et al*. Efficacy of face mask in preventing respiratory virus transmission: A systematic review and meta-analysis. *Travel Med Infect Dis* 2020; published online May 28. DOI:10.1016/j.tmaid.2020.101751.
- 5 Chu DK, Akl EA, Duda S, *et al*. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *The Lancet* 2020; **395**: 1973–87.
- 6 Community Initiatives. What Countries Require Masks in Public or Recommend Masks? #Masks4All. <https://masks4all.co/what-countries-require-masks-in-public/> (accessed July 16, 2020).
- 7 Andreoni M. Judge Scolds Brazil's President for Violating Mask Law. *The New York Times*. 2020; published online June 23. <https://www.nytimes.com/2020/06/23/world/americas/bolsonaro-brazil-mask.html> (accessed July 16, 2020).
- 8 Aratani L. How did face masks become a political issue in America? *the Guardian*. 2020; published online June 29. <http://www.theguardian.com/world/2020/jun/29/face-masks-us-politics-coronavirus> (accessed July 16, 2020).
- 9 Wang C, Otani Y. Removal of Nanoparticles from Gas Streams by Fibrous Filters: A Review. 2012; published online July 12. DOI:10.1021/ie300574m.
- 10 Johnson E. Filtration Mechanisms of Particulate Respirators. 2005; : 7.
- 11 World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention precautions. Geneva, Switzerland, 2020 <https://apps.who.int/iris/rest/bitstreams/1286634/retrieve>.
- 12 Fennelly KP. Particle sizes of infectious aerosols: implications for infection control. *The Lancet Respiratory Medicine* 2020; **0**. DOI:10.1016/S2213-2600(20)30323-4.
- 13 Rajagopalan S, Huang S, Brook RD. Flattening the curve in COVID-19 using personalised protective equipment: lessons from air pollution. *Heart* 2020; : heartjnl-2020-317104.
- 14 MacIntyre CR, Chughtai AA. A rapid systematic review of the efficacy of face masks and respirators against coronaviruses and other respiratory transmissible viruses for the community, healthcare workers and sick patients. *International Journal of Nursing Studies* 2020; **108**: 103629.

- 15 Morawska L, Cao J. Airborne transmission of SARS-CoV-2: The world should face the reality. *Environment International* 2020; **139**: 105730.
- 16 Wang Y, Tian H, Zhang L, *et al.* Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China. *BMJ Glob Health* 2020; **5**: e002794.
- 17 Chokephaibulkit K, Assanasen S, Apisarnthanarak A, *et al.* Seroprevalence of 2009 H1N1 Virus Infection and Self-Reported Infection Control Practices Among Healthcare Professionals Following the First Outbreak in Bangkok, Thailand. *Influenza and Other Respiratory Viruses* 2013; **7**: 359–63.
- 18 Cowling BJ, Fung ROP, Cheng CKY, *et al.* Preliminary Findings of a Randomized Trial of Non-Pharmaceutical Interventions to Prevent Influenza Transmission in Households. *PLOS ONE* 2008; **3**: e2101.
- 19 Cowling BJ, Chan K-H, Fang VJ, *et al.* Facemasks and Hand Hygiene to Prevent Influenza Transmission in Households. *Annals of Internal Medicine* 2009; **151**: 437–46.
- 20 MacIntyre CR, Wang Q, Cauchemez S, *et al.* A cluster randomized clinical trial comparing fit-tested and non-fit-tested N95 respirators to medical masks to prevent respiratory virus infection in health care workers. *Influenza Other Respir Viruses* 2011; **5**: 170–9.
- 21 Nishiura H, Kuratsuji T, Quy T, *et al.* Rapid awareness and transmission of severe acute respiratory syndrome in Hanoi French Hospital, Vietnam. *Am J Trop Med Hyg* 2005; **73**: 17–25.
- 22 Wilder-Smith A, Telean MD, Heng BH, Earnest A, Ling AE, Leo YS. Asymptomatic SARS Coronavirus Infection among Healthcare Workers, Singapore. *Emerging Infectious Diseases* 2005; **11**. DOI:10.3201/eid1107.041165.
- 23 Telean MD, Boudville IC, Heng BH, Zhu D, Leo YS. Factors associated with transmission of severe acute respiratory syndrome among health-care workers in Singapore. *Epidemiology & Infection* 2004; **132**: 797–803.
- 24 Yin W, Gao L, Lin W, *et al.* [Effectiveness of personal protective measures in prevention of nosocomial transmission of severe acute respiratory syndrome]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2004; **25**: 18–22.
- 25 Zhang Y, Seale H, Yang P, *et al.* Factors associated with the transmission of pandemic (H1N1) 2009 among hospital healthcare workers in Beijing, China. *Influenza Other Respir Viruses* 2013; **7**: 466–71.
- 26 Lau JTF, Lau M, Kim JH, Tsui H-Y, Tsang T, Wong TW. Probable secondary infections in households of SARS patients in Hong Kong. *Emerging Infect Dis* 2004; **10**: 235–43.
- 27 Wu J, Xu F, Zhou W, *et al.* Risk Factors for SARS among Persons without Known Contact with SARS Patients, Beijing, China. *Emerging Infectious Diseases* 2004; **10**. DOI:10.3201/eid1002.030730.
- 28 Liu W, Tang F, Fang L-Q, *et al.* Risk factors for SARS infection among hospital healthcare workers in Beijing: a case control study. *Tropical Medicine & International Health* 2009; **14**: 52–9.

- 29 Wang X, Pan Z, Cheng Z. Association between 2019-nCoV transmission and N95 respirator use. *J Hosp Infect* 2020; **105**: 104–5.
- 30 Wang Q, Huang X, Bai Y, *et al.* Epidemiological characteristics of COVID-19 in medical staff members of neurosurgery departments in Hubei province: A multicentre descriptive study. *medRxiv* 2020; : 2020.04.20.20064899.
- 31 Nishiyama A, Wakasugi N, Kirikae T, *et al.* Risk factors for SARS infection within hospitals in Hanoi, Vietnam. *Jpn J Infect Dis* 2008; **61**: 388–90.
- 32 Reynolds MG, Anh BH, Thu VH, *et al.* Factors associated with nosocomial SARS-CoV transmission among healthcare workers in Hanoi, Vietnam, 2003. *BMC Public Health* 2006; **6**: 207.
- 33 Seto WH, Tsang D, Yung RWH, *et al.* Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). *Lancet* 2003; **361**: 1519–20.
- 34 Ho KY, Singh KS, Habib AG, *et al.* Mild illness associated with severe acute respiratory syndrome coronavirus infection: lessons from a prospective seroepidemiologic study of health-care workers in a teaching hospital in Singapore. *J Infect Dis* 2004; **189**: 642–7.
- 35 Pei L, Gao Z, Yang Z, *et al.* Investigation of the influencing factors on severe acute respiratory syndrome among health care workers. *Beijing Da Xue Xue Bao Yi Xue Ban* 2006; **38**: 271–5.
- 36 Kim C-J, Choi WS, Jung Y, *et al.* Surveillance of the Middle East respiratory syndrome (MERS) coronavirus (CoV) infection in healthcare workers after contact with confirmed MERS patients: incidence and risk factors of MERS-CoV seropositivity. *Clin Microbiol Infect* 2016; **22**: 880–6.
- 37 Kim T, Jung J, Kim S-M, *et al.* Transmission among healthcare worker contacts with a Middle East respiratory syndrome patient in a single Korean centre. *Clin Microbiol Infect* 2016; **22**: e11–3.
- 38 Cheng VCC, Tai JWM, Wong LMW, *et al.* Prevention of nosocomial transmission of swine-origin pandemic influenza virus A/H1N1 by infection control bundle. *Journal of Hospital Infection* 2010; **74**: 271–7.
- 39 Park J, Kim B, Chung K, Hwang Y. Factors associated with transmission of Middle East respiratory syndrome among Korean healthcare workers: infection control via extended healthcare contact management in a secondary outbreak hospital. *Respirology* 2016; **21**: 89.
- 40 Ki HK, Han SK, Son JS, Park SO. Risk of transmission via medical employees and importance of routine infection-prevention policy in a nosocomial outbreak of Middle East respiratory syndrome (MERS): a descriptive analysis from a tertiary care hospital in South Korea. *BMC Pulmonary Medicine* 2019; **19**: 190.
- 41 Ha LD, Bloom SA, Hien NQ, *et al.* Lack of SARS Transmission among Public Hospital Workers, Vietnam. *Emerg Infect Dis* 2004; **10**: 265–8.
- 42 Tuan PA, Horby P, Dinh PN, *et al.* SARS transmission in Vietnam outside of the health-care setting. *Epidemiol Infect* 2007; **135**: 392–401.

- 43 Loeb M, McGeer A, Henry B, *et al.* SARS among Critical Care Nurses, Toronto. *Emerg Infect Dis* 2004; **10**: 251–5.
- 44 Scales DC, Green K, Chan AK, *et al.* Illness in Intensive Care Staff after Brief Exposure to Severe Acute Respiratory Syndrome. *Emerg Infect Dis* 2003; **9**: 1205–10.
- 45 Heinzerling A. Transmission of COVID-19 to Health Care Personnel During Exposures to a Hospitalized Patient — Solano County, California, February 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**. DOI:10.15585/mmwr.mm6915e5.
- 46 Park BJ, Peck AJ, Kuehnert MJ, *et al.* Lack of SARS Transmission among Healthcare Workers, United States. *Emerg Infect Dis* 2004; **10**: 217–24.
- 47 Peck AJ, Newbern EC, Feikin DR, *et al.* Lack of SARS transmission and U.S. SARS case-patient. *Emerging Infect Dis* 2004; **10**: 217–24.
- 48 Burke RM, Balter S, Barnes E, *et al.* Enhanced Contact Investigations for Nine Early Travel-Related Cases of SARS-CoV-2 in the United States. *medRxiv* 2020; : 2020.04.27.20081901.
- 49 Barasheed O, Almasri N, Badahdah A-M, *et al.* Pilot Randomised Controlled Trial to Test Effectiveness of Facemasks in Preventing Influenza-like Illness Transmission among Australian Hajj Pilgrims in 2011. *Infect Disord Drug Targets* 2014; **14**: 110–6.
- 50 Suess T, Remschmidt C, Schink SB, *et al.* The role of facemasks and hand hygiene in the prevention of influenza transmission in households: results from a cluster randomised trial; Berlin, Germany, 2009–2011. *BMC Infectious Diseases* 2012; **12**: 26.
- 51 Sung AD, Sung JAM, Thomas S, *et al.* Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. *Clin Infect Dis* 2016; **63**: 999–1006.
- 52 Zhang L, Peng Z, Ou J, *et al.* Protection by Face Masks against Influenza A(H1N1)pdm09 Virus on Trans-Pacific Passenger Aircraft, 2009. *Emerging Infectious Diseases* 2013; **19**. DOI:10.3201/eid1909.121765.
- 53 Alraddadi BM, Al-Salmi HS, Jacobs-Slifka K, *et al.* Risk Factors for Middle East Respiratory Syndrome Coronavirus Infection among Healthcare Personnel. *Emerg Infect Dis* 2016; **22**: 1915–20.
- 54 Jaeger JL, Patel M, Dharan N, *et al.* Transmission of 2009 pandemic influenza A (H1N1) virus among healthcare personnel-Southern California, 2009. *Infect Control Hosp Epidemiol* 2011; **32**: 1149–57.
- 55 Hall AJ, Tokars JI, Badreddine SA, *et al.* Health care worker contact with MERS patient, Saudi Arabia. *Emerging Infect Dis* 2014; **20**: 2148–51.
- 56 Zhang L. Study on correlation between nosocomial respiratory virus infection and use of disposable respirator in medical staff. *Nursing Practice and Research* 2017; **14**. DOI:10.3969/j.issn.1672-9676.2017.22.046.
- 57 Aiello AE, Perez V, Coulborn RM, Davis BM, Uddin M, Monto AS. Facemasks, Hand Hygiene, and Influenza among Young Adults: A Randomized Intervention Trial. *PLOS ONE* 2012; **7**: e29744.

- 58 Ryu B, Cho S-I, Oh M-D, *et al.* Seroprevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) in public health workers responding to a MERS outbreak in Seoul, Republic of Korea, in 2015. *Western Pac Surveill Response J* 2019; **10**: 46–8.
- 59 Ma H, Wang H, Fang L, *et al.* [A case-control study on the risk factors of severe acute respiratory syndromes among health care workers]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2004; **25**: 741–4.
- 60 Zheng P, Aravkin A, Barber R, Sorensen R, Murray C. Trimmed Constrained Mixed Effects Models: Formulations and Algorithms. *Bioinformatics*, 2020 DOI:10.1101/2020.01.28.923599.
- 61 Fan J, Li Y, Stewart K, *et al.* COVID-19 World Survey Data API. 2020. <https://covidmap.umd.edu/api.html> (accessed July 19, 2020).
- 62 Huprikar S, Ludolph T. Are Americans Wearing Face Masks? Premise. 2020; published online June 4. <https://www.premise.com/are-americans-wearing-face-masks/> (accessed July 16, 2020).
- 63 Jones SP, Imperial College London Big Data Analytical Unit, YouGov Plc. YouGov Covid Data Hub, v1.0. YouGov Plc., 2020 <https://github.com/YouGov-Data/covid-19-tracker> (accessed July 19, 2020).
- 64 Reiner Jr. R, Barber R, Zheng P, *et al.* COVID-19 scenarios for the United States. *Infectious Diseases (except HIV/AIDS)*, 2020 DOI:10.1101/2020.07.12.20151191.
- 65 Roth GA, Abate D, Abate KH, *et al.* Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet* 2018; **392**: 1736–88.
- 66 Friedman J, Liu P, Gakidou E, IHME COVID-19 Model Comparison Team. Predictive performance of international COVID-19 mortality forecasting models. *Epidemiology*, 2020 DOI:10.1101/2020.07.13.20151233.
- 67 Davis N. Report on face masks’ effectiveness for Covid-19 divides scientists. *The Guardian*. 2020; published online May 4. <https://www.theguardian.com/world/2020/may/04/scientists-disagree-over-face-masks-effect-on-covid-19> (accessed July 16, 2020).
- 68 Face Masks for the General Public. Royal Society DELVE Initiative. 2020; published online May 4. <http://rs-delve.github.io/reports/2020/05/04/face-masks-for-the-general-public.html> (accessed July 16, 2020).
- 69 Wang Y, Tian H, Zhang L, *et al.* Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China. *BMJ Glob Health* 2020; **5**: e002794.
- 70 Leung NHL, Chu DKW, Shiu EYC, *et al.* Respiratory virus shedding in exhaled breath and efficacy of face masks. *Nature Medicine* 2020; **26**: 676–80.
- 71 Hendrix MJ. Absence of Apparent Transmission of SARS-CoV-2 from Two Stylists After Exposure at a Hair Salon with a Universal Face Covering Policy — Springfield, Missouri, May 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**. DOI:10.15585/mmwr.mm6928e2.

- 72 Bielecki M, Züst R, Siegrist D, *et al.* Social distancing alters the clinical course of COVID-19 in young adults: A comparative cohort study. *Clinical Infectious Diseases* 2020; : ciaa889.
- 73 Wang X, Ferro EG, Zhou G, Hashimoto D, Bhatt DL. Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. *JAMA* 2020; published online July 14. DOI:10.1001/jama.2020.12897.
- 74 CDC. Coronavirus Disease 2019 (COVID-19) : Use of masks to help slow the spread of COVID-19. Centers for Disease Control and Prevention. 2020; published online Feb 11. <https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/diy-cloth-face-coverings.html> (accessed Aug 2, 2020).
- 75 Iversen BG, Vestrheim D, Flottorp S, Denison E, Oxman A, Norwegian Institute of Public Health. Should individuals in the community without respiratory symptoms wear facemasks to reduce the spread of COVID-19? *Norwegian Institute of Public Health* 2020; : 45.
- 76 Zaken M van A. Avoid busy places and stay 1.5 metres away from others. 2020; published online May 6. <https://www.government.nl/latest/news/2020/05/06/avoid-busy-places-and-stay-1.5-metres-away-from-others> (accessed July 16, 2020).
- 77 The Public Health Agency of Sweden. FAQ about COVID-19. <http://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/covid-19/> (accessed July 16, 2020).
- 78 Wong T. Coronavirus: Why some countries wear face masks and others don't - BBC News. <https://www.bbc.com/news/world-52015486> (accessed July 16, 2020).
- 79 World Health Organization. Advice on the use of masks in the context of COVID-19: Interim guidance. Geneva, Switzerland, 2020 [https://apps.who.int/iris/bitstream/handle/10665/332293/WHO-2019-nCov-IPC\\_Masks-2020.4-eng.pdf?sequence=1&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/332293/WHO-2019-nCov-IPC_Masks-2020.4-eng.pdf?sequence=1&isAllowed=y).

## Code Availability Statement

Our study follows the Guidelines for Accurate and Transparent Health Estimate Reporting. All code used for these analyses is publicly available online (<http://github.com/ihmeuw/>).

## Online content

Results for each scenario are accessible through a visualization tool at <http://covid19.healthdata.org>. The estimates presented in this tool will be iteratively updated as new data are incorporated and will ultimately supersede the results in this paper.

## Acknowledgments

We thank the various Departments of Health and frontline health professionals who are not only responding to this epidemic daily, but also provide the necessary data to inform this work – IHME wishes to warmly acknowledge the support of these and others (<http://www.healthdata.org/covid/acknowledgements>) who have made our COVID-19 estimation efforts possible. This work was supported by the Bill & Melinda Gates Foundation, Bloomberg Philanthropies, as well as funding from the state of Washington and the National Science Foundation (2031096). We also extend a note of particular thanks to John Stanton and Julie Nordstrom for their generous support. We are grateful to Professor Wei Huang from Peking University for helping us extract information from scientific papers in Chinese.

## Competing interests

This study was funded by the Bill & Melinda Gates Foundation and Bloomberg Philanthropies. The funders of the study had no role in study design, data collection, data analysis, data interpretation, writing of the final report, or decision to publish. The corresponding author had full access to all of the data in the study and had final responsibility for the decision to submit for publication.